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ABSTRACT 
 Fibroblast growth factors (FGFs) play an essential role in development and 
patterning of the vertebrate embryo. Despite extensive literature documenting the 
diverse roles of FGF signalling during craniofacial development, comparatively little 
is known about the specific downstream effectors through which FGFs influence gene 
expression. A previous study in our laboratory reported exogenous FGF elicited 
differential chondrogenic responses in frontonasal and mandibular mesenchyme 
(Bobick et al., 2007). Pea3 transcription factors are crucial components of the 
downstream effector pathway through which FGFs influence gene expression (Raible 
and Brand, 2001).  Therefore, the purpose of my research was to examine whether 
differences in pea3, erm, and er81 gene expression profiles underlie the distinct 
responses of the frontonasal and mandibular mesenchyme cells to FGF. 
 The present study demonstrates that FGF2 treatment differentially affects 
chondrogenesis in micromass cultures of frontonasal and mandibular mesenchyme 
isolated from stage 24/25 chick embryos. Whereas FGF2 inhibited chondrogenesis in 
frontonasal mesenchyme cultures, it had no effect on micromass cultures of 
mandibular mesenchyme. RT-qPCR and RNA dot blot analyses demonstrated that 
mRNA transcripts for the pea3, erm, and er81 genes are expressed by mesenchyme 
cells of both frontonasal and mandibular processes of stage 24/25 and stage 28/29 
chick embryos. In addition, western blot data demonstrated expression of the Pea3 
and Er81 proteins in micromass and explant cultures of stage 24/25 frontonasal and 
mandibular mesenchyme. 
 The expression profiles of Pea3 genes were similar between the frontonasal 
and mandibular facial primordia prior to treatment with exogenous FGF2. However, 
these expression profiles were differentially altered in response to FGF2 exposure in 
both explant and micromass cultures. Specifically, whereas FGF2 treatment 
upregulated pea3 mRNA levels in explants of frontonasal mesenchyme, it had no 
effect on pea3 expression in mandibular explants. In micromass cultures, exogenous 
FGF2 elevated levels of pea3 transcripts in both frontonasal and mandibular 
mesenchyme. However, FGF2 treatment elevated er81 expression in frontonasal, but 
not mandibular mesenchyme. Conversely, exogenous FGF2 elevated erm mRNA 
levels in mandibular, but not frontonasal mesenchyme.  
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 Micromass cultures of mandibular mesenchyme from stage 28/29 chick 
embryos exhibited significantly lower levels of pea3 expression than cultures of stage 
24/25 mandibular mesenchyme. This stage-dependent change correlated with a 
reduction in the ability of the mandibular cells to undergo spontaneous chondrogenic 
differentiation in micromass culture. In contrast, no stage-dependent changes in pea3 
expression were observed in frontonasal mesenchyme cultures.  
 Collectively, my data indicate that the expression profiles of pea3, erm, and 
er81 in frontonasal and mandibular mesenchyme become distinct only after exposure 
to exogenous FGF. This raises the possibility that the differences in Pea3 transcription 
factor expression patterns that arise in response to FGF stimuli may subsequently lead 
to distinct chondrogenic responses in the two facial mesenchyme populations.   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1 INTRODUCTION  
1.1 Role of Cartilage in Skeletal Development  
 The majority of the vertebrate skeleton is derived from hyaline cartilage 
templates established during the embryonic period. This includes bones of the axial 
and appendicular skeleton, ribs and sternum, floor of the skull, and some portions of 
the facial skeleton (Cancedda et al., 1995). Therefore, clarifying mechanisms 
involved in the regulation of embryonic cartilage tissue formation (chondrogenesis) is 
crucial for understanding both normal skeletal development and the basis of many 
congenital skeletal malformations.  
 The vertebrate skeleton is comprised of cells from three distinct lineages: the 
somatopluere of the lateral plate mesoderm, the scleratome of the paraxial mesoderm, 
and the neural crest cells of the neural plate. During embryogenesis mesenchymal 
chondroprogenitor cells from these distinct lineages migrate to the prospective sites of 
skeletal elements (Hall and Miyake, 2000). Embryonic cartilage formation is 
ultimately derived from aggregates, or condensations, of mesenchymal 
chondroprogenitor cells within these sites. The origin of these mesenchymal 
chondroprogenitor cells varies within different regions of the body. The somatopleure 
of the lateral plate mesoderm gives rise to the cartilage templates of the long bones of 
the appendicular skeleton and sternum. The scleratome of the paraxial mesoderm 
yields the cartilage precursors of the axial skeleton (vertebrae and ribs), while neural 
crest cells that emerge from the margins of the neural plate give rise to the 
cartilaginous templates of the anterior portion of the base of the skull and some facial 
bones (Olsen et al., 2000).  
 In most anatomical locations, embryonic cartilage is a transient structure. 
During skeletogenesis, these transient structures are gradually replaced by bone 
through a process known as endochondral ossification (Mackie et al., 2008; Mackie et 
al., 2011; Olsen et al., 2000). However, cartilage persists postnatally in distinct 
locations including within the growth plate between the epiphyses and diaphyses of 
long bones where it allows for longitudinal bone growth during 
childhood/adolescence, and as a thin layer at the articular surfaces of diarthrodal 
joints (Ross and Pawlina, 2006).  
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 Regardless of the embryonic lineage of the mesenchymal chondroprogenitor 
cells (mesoderm or neural crest derived) and their anatomical location, formation of 
the cartilaginous templates required for endochondral ossification proceeds along a 
common chondrogenic pathway (Lefebvre et al., 2001). Although a number of cell 
types are required for the step-wise progression of endochondral ossification, the 
process is ultimately driven by chondrocytes (Mackie et al., 2011).   
 The following section will summarize critical events in the various stages of 
cartilage formation. Emphasis will be placed on the early stages of chondrogenic 
differentiation, although subsequent stages of chondrocyte maturation, hypertrophy, 
and endochondral ossification will be briefly discussed.  
1.2 Stages of Cartilage Differentiation, Chondrocyte Maturation, 
and Endochondral Ossification  
1.2.1 Prechondrogenic mesenchymal condensation  
 Initiation of embryonic chondrogenesis involves the aggregation, or 
condensation of chondrogenic mesenchymal precursor cells within future regions of 
bone formation. The formation of high density, compact cellular aggregates serves to 
establish the size and position of each cartilage anlage (Goldring and Goldring, 1990). 
Aggregation also serves to permit crucial cell-cell interactions and signalling events 
that lead to overt chondrogenic differentiation (Hall and Miyake, 2000). 
 Initially, a transient extracellular matrix is produced by prechondrogenic 
mesenchymal cells at the sites of prospective cartilage formation. This transient 
extracellular matrix regulates both the aggregation and overt differentiation of 
mesenchymal cells into chondrocytes (Hall and Miyake, 2000). The unique 
composition of molecules present within the transient extracellular matrix provides 
insight into cellular progression throughout the distinct stages of chondrogenic 
differentiation (McAlinden et al., 2005).  
 In particular, the condensation of prechondrogenic mesenchyme is 
characterized by expression of type II collagen, the predominant collagen component 
of cartilage extracellular matrix in both adult and embryonic tissues (Kosher et al., 
1986a; Nah et al., 1988). Type II collagen is first synthesized as pro-collagen 
polypeptides consisting of three identical α1 (II) chains, each of which contains both 
amino and carboxyl terminal pro-peptide sequences (Ala-Kokko et al., 1995). Within 
the endoplasmic reticulum, pro-collagen α1 (II) chains assemble into heterotrimers. 
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Hydroxylation of proline and lysine residues of the α1 (II) chains results in the 
formation of triple helical pro-collagen molecules which are transported to the golgi 
apparatus where glycosylation occurs. The triple pro-collagen molecules are then 
secreted from the cells where the amino and carboxy terminal propeptide sequences 
are excised. Within the extracellular spaces, the resulting tropocollagen molecules 
undergo cross linking to form mature type II collagen fibrils (McAlinden et al., 2005). 
These collagen fibrils, which contain primarily type II collagen but also small 
amounts of type IX and XI collagens, function to provide tensile strength and assist in 
the organization of the extracellular matrix (McAlinden et al., 2005). 
 The gene transcripts of the col2a1 gene are alternatively spliced, generating 
two distinct mRNA isoforms, type IIA and IIB pro-collagens. Stages of chondrocyte 
differentiation are distinguishable on the basis of which type II collagen isoform 
predominates. Specifically, condensations of mesenchymal chondroprogenitor cells 
express type IIA pro-collagen mRNA transcripts, whereas expression of type IIB 
collagen is characteristic of differentiated chondrocytes (Ryan and Sandell, 1990).  
 Another collagen present within the transient extracellular matrix of 
aggregating prechondrogenic mesenchyme cells is Type I collagen. Although type I 
collagen is not present within mature hyaline cartilage extracellular matrix, it is 
thought to be involved in regulating condensation of prechondrogenic mesenchyme 
and overt chondrogenic differentiation (Bobick et al., 2009). In immunohistochemical 
studies of embryonic chick limb mesenchyme micromass cultures, Dessau et al. 
(1980) demonstrated the extracellular matrix of mesenchymal chondroprogenitor cells 
is rich in type I collagen prior to overt chondrogenesis (Dessau et al., 1980). 
Moreover, during condensation of these cells, type I collagen expression increases 
(DeLise et al., 2000).  
 In addition to the type II collagen fibrils, a large keratan sulphate/chondroitin 
sulphate rich proteoglycan known as aggrecan is the second major constituent of the 
cartilage extracellular matrix (Bobick et al., 2009). The highly sulphated 
glyscosaminoglycan (GAG) chains of aggrecan are negatively charged, attracting 
osmotically active cations, which in turn draw large amounts of water into the 
extracellular matrix. Aggrecan monomers assemble within the extracellular matrix 
into large aggregates that are non-covalently bound to hyaluronan. Expression of 
aggrecan gene transcripts begins at the onset of condensation of prechondrogenic 
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mesenchymal cells. Moreover, aggrecan expression is almost exclusively limited to 
cartilage tissue (Sai et al., 1986).  
 Increased cell-cell contacts during condensation of prechondrogenic 
mesenchyme are mediated by a number of cell surface adhesion molecules, including 
neural cadherin (N-cadherin) and neural cell adhesion molecule (N-CAM) (DeLise et 
al., 2000). N-cadherin is a single-pass transmembrane glycoprotein, whereas N-CAM, 
belonging to the immunoglobulin superfamily of cell adhesion molecules, is a 
homophilic calcium-dependent binding protein. Both types of cell adhesion molecules 
are abundantly expressed at the surfaces of prechondrogenic mesenchymal cells 
(Oberlender and Tuan, 1994). Using a monoclonal antibody directed against N-
cadherin, Oberlender et al. (1994) demonstrated that reduced N-cadherin activity 
inhibited chondrogenesis in chick limb bud mesenchyme micromass cultures 
(Oberlender and Tuan, 1994). This chondro-inhibitory effect, however, was time 
dependent, as the effect of the antibody treatment was only observed during 
condensation of prechondrogenic mesenchyme (Oberlender and Tuan, 1994).  
Similarly, Widelitz et al. (1993) demonstrated functional reduction of N-CAM 
activity inhibits chondrogenesis in chick limb bud mesenchyme micromass cultures 
(Widelitz et al., 1993). These studies suggest that N-cadherin and N-CAM both 
function as positive regulators of early stages of chondrogenic differentiation.  
 Fibronectin and syndecan-3, two additional extracellular matrix 
macromolecules, have also been implicated in the regulation of condensation of 
prechondrogenic mesenchyme cells (DeLise et al., 2000). Fibronectin, a large 
glycoprotein, is secreted into the extracellular space as a dimer composed of two 
subunits linked by a pair of disulfide bonds within their carboxyl termini. Upon 
secretion, additional disulfide bonds form between fibronectin dimers creating large 
stable polymers (DeLise et al., 2000). As chondrogenesis proceeds, fibronectin 
mRNA gene transcripts, like those of type II collagen, undergo alternative gene 
splicing events to yield numerous isoforms (DeLise et al., 2000). Within the pre-
cartilage extracellular matrix, the fibronectin isoform containing the exon EIIIA is 
abundantly present, in addition to isoforms IIIB and V. Notably, expression of the 
EIIIA-containing fibronectin isoform ceases upon overt initiation of chondrogenic 
differentiation (DeLise et al., 2000). The switch in regulation of fibronectin mRNA 
alternative splicing occurs after the condensation of prechondrogenic mesenchyme, as 
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antibodies directed against the region encoding the EIIIA exon prevent cellular 
condensation of prechondrogenic mesenchymal cells in vitro (Gehris et al., 1997). 
This evidence strongly suggests the EIIIA fibronectin isoform is required for the 
condensation events associated with early stages of chondrogenesis.  
 Additional evidence suggests that syndecan-3, a transmembrane heparan 
sulphate proteoglycan is also involved in regulation of condensation events of 
prechondrogenic mesenchyme (Gould et al., 1995). In situ hybridization studies have 
revealed that condensations of chick limb prechondrogenic mesenchyme express high 
levels of syndecan-3 (Koyama et al., 1995). Syndecan-3 plays an important role in 
establishing the boundaries of condensations of prechondrogenic mesenchyme, 
thereby limiting the size of such condensations (Hall and Miyake, 2000). 
 Tenascin-C, a large extracellular matrix glycoprotein, is closely associated 
with syndecan-3 (Hall and Miyake, 2000). During condensation of chondrogenic 
mesenchymal precursor cells, expression levels of tenascin-C are high. Non-
chondrogenic mesenchyme cells situated near such condensations, however, do not 
express tenascin-C (Mackie and Murphy, 1998). Although Tenascin-C is believed to 
function alongside syndecan-3 to set the boundaries of prechondrogenic mesenchyme 
condensations (Hall and Miyake, 2000), the exact nature of its involvement remains 
unclear, as tenascin-C knockout mice develop normally (Saga et al., 1992). 
 Hyaluronan, also called hyaluronic acid, is a large non-sulphated, non-
branched glycosaminoglycan consisting of a repeating disaccharide of glucuronic acid 
and N-acetyl glucosamine (Bastow et al., 2008). In contrast to other 
glycosaminoglycans, hyaluronan is not covalently linked to a core protein (Laurent 
and Fraser, 1992). During embryonic development, hyaluronan is abundantly present 
within the extracellular matrices of migrating and proliferating cells (Knudson and 
Knudson, 1993). Within the precartilage matrix, Hyaluronan is thought to facilitate 
migration of prechondrogenic mesenchyme cells (Bastow et al., 2008), and to assist in 
regulation of condensation initiation by limiting mesenchymal cell-cell interactions 
through interactions with other matrix molecules and cell surface hyaluronan-binding 
proteins (Knudson and Knudson, 1993). Specifically, the expression of CD44, a well 
characterized hyaluronan-binding cell surface receptor, coincides with the 
condensation events associated with early stages of chondrogenic differentiation 
(Rousche and Knudson, 2002). As condensation proceeds, extracellular levels of 
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Hyaluronan decline. In addition, hyaluronidase activity, the enzyme responsible for 
hyaluronan degradation, increases throughout the condensation process (Kulyk and 
Kosher, 1987). Importantly, some hyaluronan continues to be produced by 
differentiating chondrocytes and serves as a scaffold upon which aggrecan monomers 
align, forming supramolecular complexes in the cartilage extracellular matrix 
(Laurent and Fraser, 1992).  
1.2.2 Initiation of chondrocyte differentiation and cartilage matrix production   
 The close proximity and intimate cell-cell interactions within the cellular 
condensations permits the subsequent initiation of overt chondrogenesis (Bobick and 
Kulyk, 2008). Chondrogenic precursors undergo extensive phenotypic changes, 
exchanging their stellate, fibroblastic morphology for the more spherical morphology 
typical of mature chondrocytes (Hoffman et al., 2003). Differentiating chondrocytes 
within these cellular aggregates then begin to synthesize cartilage specific 
extracellular matrix molecules, such as collagen type II, IX, and XI (Bobick and 
Kulyk, 2008). Moreover, the expression patterns of many of the genes involved in the 
condensation events of early chondrogenesis are dramatically altered.  
 For example, while type I collagen is abundantly expressed within the 
extracellular matrices of condensed prechondrogenic mesenchymal cells, its 
expression ceases at the onset of overt chondrogenic differentiation (DeLise et al., 
2000). Moreover, while the predominant collagen within the extracellular matrices of 
chondroprogenitor cells is collagen type IIA, the onset of overt chondrogenic 
differentiation is marked by a switch to expression of collagen type IIB (Bobick and 
Kulyk, 2008). Interestingly, while collagen type IIA is also expressed by certain other 
embryonic cell types, the expression of type IIB collagen is almost exclusively limited 
to differentiated chondrocytes (McAlinden et al., 2005). During overt chondrogenic 
differentiation there is a progressive increase in both type II collagen and aggrecan 
levels which parallels the progressive increase in extracellular matrix accumulation 
(Kosher et al., 1986b). The restricted expression of type II collagen and aggrecan in 
hyaline cartilage enables their routine use as molecular markers of differentiated 
chondrocytes in vitro.  
 N-cadherin and N-CAM cease to be expressed following overt differentiation 
of prechondrogenic mesenchyme cells into chondrocytes (Oberlender and Tuan, 
1994). Similarly, syndecan-3 is absent from the extracellular matrix of fully 
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differentiated chondrocytes (Gould et al., 1995) and expression of both tenascin-c and 
fibronectin isoform EIIIA declines greatly (Mackie and Murphy, 1998). In contrast, 
low levels of fibronectin IIIB and V isoform expression persist (DeLise et al., 2000).  
1.2.3 Chondrocyte maturation and hypertrophy   
 Within the adult vertebrate skeleton, hyaline cartilage persists only in 
restricted regions of the body (i.e., articular cartilage at diarthrodal joint surfaces; 
costal cartilage in the rib cage and nasal septum cartilage). In all other regions, the 
cartilaginous skeletal elements that were formed during embryogenesis are replaced 
by bone through the process of endochondral ossification.  
 This process is initiated within the center of the hyaline cartilage template 
where the chondrocytes cease proliferating and mature to a stage of terminal 
differentiation known as hypertrophy, which is characterized by a dramatic increase 
in chondrocyte diameter and volume (Stanton et al., 2003). Importantly, hypertrophic 
chondrocytes cease to express type II collagen and instead begin to produce type X 
collagen, a non-fibrillar collagen comprised of three identical α1(X) polypeptide 
chains. Type X collagen is a secretory product unique to hypertrophic chondrocytes 
and a characteristic molecular marker of hypertrophic cartilage matrix (Poole, 2000). 
As chondrocytes undergo hypertrophy, their cytoplasmic alkaline phosphatase activity 
rises dramatically (Mackie et al., 2008) and  their extracellular matrix becomes 
mineralized through hydroxyapatite deposition. Concurrently, the hypertrophic 
chondrocytes release vascular angiogenic growth factor (VEGF) which stimulates the 
invasion of blood vessels from surrounding perichondrial tissue. This enables both 
bone-forming osteoblasts and cartilage-degrading chondroclasts to infiltrate the 
calcified cartilage matrix. Most of the hypertrophic chondrocytes subsequently die, 
although some may transform into osteoblast-like cells. The specific mechanism by 
which hypertrophic chondrocytes die is currently the subject of much debate (Shapiro 
et al., 2005).  
1.2.4 Endochondral Ossification 
 
 The process of endochondral ossification, in which the mineralized cartilage 
tissue is gradually replaced by bone, follows the preceding events. This begins in the 
primary ossification center located in the middle region of each embryonic cartilage 
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template. Therein, the chondroclasts that invaded the hypertrophic cartilage tissue 
proceed to erode much of the mineralized extracellular matrix (Mackie et al., 2008). 
However, some calcified cartilaginous extracellular matrix persists and serves as a 
scaffold for the deposition of osteoid by the infiltrating osteoblasts. The type I 
collagen-rich osteoid matrix is subsequently calcified. The resulting woven bone 
overlying the calcified cartilage extracellular matrix is subsequently resorbed by 
osteoclasts, and replaced by mature bone (Mackie et al., 2008; Mackie et al., 2011; 
Olsen et al., 2000). At later embryonic or early postnatal stages, the sequence of 
endochondral ossification events begins within secondary ossification centers located 
at the distal epiphyseal ends of each cartilage template. However, disc-shaped 
“growth plates” of metabolically active cartilage tissue remain situated between the 
primary and secondary ossification centers at both ends of the developing long bone. 
The processes of chondrocyte proliferation, hypertrophy, and endochondral 
ossification continue within these growth plates throughout childhood and 
adolescence, which drives longitudinal elongation of the growing bones (Ross and 
Pawlina, 2006).  
1.3 Development and Cartilage Formation in Embryonic Facial 
Primordia 
  
 All vertebrates share a common craniofacial morphology in early stages of 
embryonic development (Liu et al., 2010).  The primitive vertebrate face consists of 
distinct primordia, discrete buds of neural crest- and mesoderm-derived mesenchyme. 
These four distinct facial primordia (frontonasal, mandible, maxilla, and hyoid 
prominences) are arranged in a similar pattern encircling a primitive oral cavity 
(Francis-West et al., 1998). Differential growth and cartilage formation within the 
facial primordia are predominant factors in determining face shape. As such, 
disruption of the cellular signalling cascades involved in outgrowth of the facial 
primordia can result in numerous congenital malformations including Treacher-
Collins and Alagilles syndromes, and more commonly orofacial clefts (Winter, 1996). 
 The formation of all four facial primordia involves migration of neural crest 
derived ectomesenchyme cells (Wedden et al., 1988). The frontonasal prominence is 
derived from migrating anterior cranial neural crest cells, while the more posterior 
cranial neural crest cells give rise to the pharyngeal arches (Santagati and Rijli, 2003). 
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The first pharyngeal arch gives rise to both the mandibular and maxillary facial 
prominences, while the hyoid prominence is derived from the second pharyngeal arch 
(Richman and Lee, 2003). Myogenic precursor cells derived from the paraxial 
mesoderm also migrate into the developing facial primordia. These cells will 
ultimately give rise to the skeletal muscles of the face.  Following the migration of 
cranial neural crest cells into the embryonic facial primordia, the cells aggregate into 
compact cellular arrangements, and initiate differentiation into either chondrocytes or 
osteocytes (Richman and Lee, 2003).  
 Within the avian embryo, some facial structures form via endochondral 
ossification of cartilaginous templates, while other form through intramembranous 
ossification. Within the frontonasal and mandibular process, both chondrogenesis and 
intramembranous ossification occur. The frontonasal primordia of developing chick 
embryos will ultimately form skeletal elements such as pre-nasal cartilage and the 
pre-maxillary bone (i.e. portions of the upper beak), whereas the mandibular process 
gives rise to Meckel’s cartilage and the membranous bones of the lower beak 
(angular, suprangular, splenary, and dentary bones). Within the maxillary process, 
only intramembranous ossification occurs forming maxillary, jugal, quadratojugal, 
palatine and pterygoid bones. Finally, endochondral ossification within the hyoid 
process gives rise to skeletal elements such as the columella, ceratobranchial, 
epibranchial, and basibranchial cartilages (Richman and Lee, 2003). 
 The vertebrate hindbrain is a key source of patterning information within the 
embryonic head. During early embryogenesis, the hindbrain is transiently divided into 
eight segments known as rhombomeres (r). The identity of each rhombomere is based 
upon a unique expression pattern of hox genes. Hox gene expression patterns are both 
highly ordered and partially overlapping. Moreover, Hox gene expression patterns are 
critical for ensuring proper spatial organization of the cranial neural crest cell 
migration pathways and development of the facial primordia (Cobourne, 2000). 
Migrating cranial neural crest cells from the anterior portion of the neural crest (up to 
the level of r2) do not express hox genes (Hox-negative), whereas those from more 
posterior positions (from r3 to r8) express hox genes (Hox-positive). In the avian 
embryo, the frontonasal primordia and the first pharyngeal arch, which gives rise to 
both the mandibular and maxillary primordia, are populated by Hox-negative cells. 
The second pharyngeal arch, which gives rise to the hyoid primordia, is populated by 
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Hox-positive cells. The overall pattern of the developing skeletal system is specified, 
in part, by distinct patterns of Hox gene expression, which provide positional 
information to cells of early mesenchymal lineages (Erlebacher et al., 1995). 
Additional skeletal patterning information is also provided via localized regulation of 
prechondrogenic mesenchyme condensation via secreted paracrine/autocrine factors.  
 Epithelial-mesenchymal interactions are critical factors involved in cellular 
differentiation and patterning within the developing embryo (Greene and Pisano, 
2004). Much of our knowledge of the molecular events controlling morphogenesis 
and pattern formation during skeletal development has come from experimental 
studies of the factors involved in embryonic limb bud outgrowth (Wedden et al., 
1988). Outgrowth of the embryonic limb bud is directed by the epithelium of the 
apical ectodermal ridge (AER) located at the distal tip of the limb bud. The AER is 
responsible for maintaining the underlying chondrogenic and myogenic mesenchyme 
in a proliferative, undifferentiated state (Summerbell, 1974). As proliferating limb 
mesenchyme cells emerge from the “subridge/progress” zone beneath the AER, they 
initiate overt histogenesis of cartilage and muscle tissues in a proximal to distal 
sequence. Ectodermal signalling has also been implicated in anterior-posterior limb 
axis patterning, as reversal of the ectoderm 180° about its anterior-posterior axis 
within the developing limb results in an inversion of limb skeletal elements (MacCabe 
et al., 1974).  Evidence suggests outgrowth and skeletal patterning along the dorsal 
ventral axis is regulated by several factors secreted from the ectoderm, including Wnt-
7a and Fibroblast growth factors (FGF2, -4, and-8) (Francis-West et al., 1998). 
 Establishment of the anterior-posterior axis appears to involve mesodermal 
cells located at the posterior edge of the developing limb, within the zone of 
polarizing activity (ZPA) (Wedden et al., 1988). Transplantation of cells from the 
ZPA to the anterior border of the developing limb resulted in mirror image 
duplication of skeletal structures (Maccabe et al., 1973). Sonic hedgehog (Shh), a 
secreted factor expressed within the dorsal ectoderm, is largely believed responsible 
for cellular specification along the anterior-posterior axis (Francis-West et al., 1998).   
 While considerably less is known about specific mechanisms governing the 
patterning of facial skeletal structures, it is clear this regulation also involves 
epithelial-mesenchymal interactions (Brugmann et al., 2006). For example, studies 
have shown that removal of the epithelium in the developing mandibular primordia 
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halts proximal-distal outgrowth of the underlying mesenchyme (Richman et al., 1997; 
Wedden et al., 1988). Moreover, the resulting mesenchyme begins premature 
differentiation into cartilage and bone, suggesting the mandibular epithelium has 
chondro-inhibitory effects on the underlying mesenchyme (Mina et al., 1994). In 
addition, experimental evidence suggests that signalling centers analogous to the AER 
and ZPA of the developing limb are also present within the embryonic face (Helms et 
al., 1997).  
 Prechondrogenic mesenchyme cells isolated from distinct embryonic facial 
regions exhibit differences in their levels and patterns of spontaneous chondrogenic 
differentiation in vitro (Hoffman and Kulyk, 1999). In high density micromass 
cultures, mesenchyme isolated from the frontonasal and mandibular processes 
undergo extensive spontaneous chondrogenesis, yet mesenchyme isolated from the 
maxillary or hyoid process exhibit minimal levels of spontaneous chondrogenesis 
(Hoffman and Kulyk, 1999). In addition, micromass cultures of frontonasal 
mesenchyme form irregular patches of cartilage tissue, where mandibular 
mesenchyme cultures form discrete spherical cartilage nodules (Hoffman and Kulyk, 
1999). The different in vitro behaviours of these facial mesenchyme cell populations 
is a reflection of their distinct in vivo cellular fates, and transplantation studies 
demonstrate that facial mesenchyme cells are at least partially committed to form 
specific skeletal structures even prior to migration from their sites of origin within the 
neural crest (Noden, 1991). In addition, the relative proportions of mesoderm-derived 
myogenic cells and neural crest derived skeletogenic cells, which come to reside 
within the four distinct facial primordia, may affect their capacity for chondrogenesis 
in vitro (Hoffman and Kulyk, 1999; Kulyk and Reichert, 1992).  
1.4 Transcription Factors Implicated in Chondrogenic 
Differentiation and Maturation  
 
 A large number of transcription factors are involved in the regulation of 
chondrogenic differentiation of mesenchymal cells within the developing facial 
primordia (Akiyama and Lefebvre, 2011; Hartmann, 2009).  
 Sox9, a transcription factor of the SRY-related HMG box family, is often 
considered to be the master regulator of chondrogenic differentiation. Sox9 is both 
required and sufficie(Ross et al., 2003)t for chondrocyte specification and 
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differentiation (Akiyama and Lefebvre, 2011). Heterozygous loss of function 
mutations in the human sox9 gene cause campomelic dysplasia, a severe form of 
dwarfism, and affected infants die soon after birth (Wagner et al., 1994). Since 
homozygous sox9 deficiency results in early embryonic lethality, Bi et al. (1999) 
investigated the role of Sox9 in chondrogenesis by injecting homozygous sox9 null 
embryonic stem cells (sox9-/-) into wild-type (sox9+/+) mouse blastocysts to generate 
embryonic chimeras (Bi et al., 1999). The skeletal elements that developed in these 
chimeras lacked sox9-/- cells, and were comprised solely of wild type cells. In 
addition, cartilage specific marker genes, such as type II collagen and aggrecan, failed 
to be expressed in homozygous sox9 null cells (Bi et al., 1999). Kulyk et al. (2000) 
demonstrated that the onset of Sox9 expression occurs prior to overt chondrogenesis 
in vitro, as neither type IIA collagen or aggrecan are detectable prior to Sox9 
expression (Kulyk et al., 2000). 
 Both chondrogenic mesenchyme precursor cells and fully differentiated 
chondrocytes co-express two additional members of the sox family, L-Sox5 and Sox6 
that act cooperatively with Sox9 (Lefebvre et al., 1998). Evidence suggests the nature 
of this cooperative activity is to enhance Sox9 binding on enhancers of chondrocyte 
specific genes, such as type II collagen, thereby increasing transcriptional activation 
of Sox9 responsive genes (Han and Lefebvre, 2008). L-Sox5 and Sox6 are markedly 
similar in structure, and are believed to be functionally redundant in regulation of 
chondrogenic differentiation. L-sox5:sox6 double null mutant mice develop severe, 
generalized chondrodysplasias characterized by a dramatic reduction in overall 
cartilage formation. However, mice with a homozygous deletion of only one of the L-
sox5 or sox6 genes display only mildly impaired skeletal phenotypes (Smits et al., 
2001).  
1.5 Growth Factors and Other Signalling Ligands that Control 
Cartilage Formation   
 Numerous extracellular signals, including both systemic and local soluble 
factors and components of the extracellular matrix, are involved in the regulation of 
embryonic cartilage differentiation. Of particular importance are peptide growth 
factors, as embryonic skeletal tissues are particularly receptive to their actions 
(Goldring and Goldring, 1990).   
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 Members of the transforming growth factor-β (TGFβ) superfamily are among 
the earliest signalling molecules to stimulate condensation of prechondrogenic 
mesenchyme (Goldring et al., 2006). Specifically, both TGF-β1 and TGF-β2, promote 
chondrogenesis of embryonic chick mesenchyme in vitro (Kulyk et al., 1989). TGF-β 
regulates condensation of prechondrogenic mesenchyme, in part, by increasing 
expression of both fibronectin (Leonard et al., 1991) and N-CAM (Goldring et al., 
2006). Components of the cartilage extracellular matrix interact with N-CAM to 
initiate intracellular signal transduction cascades involved in overt differentiation of 
prechondrogenic mesenchyme to mature chondrocytes (DeLise et al., 2000). 
 Other members of the TGFβ superfamily involved in regulation of 
chondrogenesis include bone morphogenetic proteins (BMPs) and activin. BMPs 
stimulate in vitro chondrogenic differentiation of chick mesenchyme (Bobick et al., 
2009). In early stages of chondrogenesis, BMPs upregulate N-cadherin expression, 
which stimulates condensation of prechondrogenic mesenchyme. Further evidence 
suggests that BMPs also regulate chondrogenesis in mouse limb bud mesenchyme 
cultures by stimulating accumulation of sox9 mRNA, a hallmark of overt 
chondrogenic differentiation (Nishimura et al., 2012; Zehentner et al., 1999). 
 Activin has also been implicated in the regulation of chondrogenesis. Jiang et 
al. (1993) demonstrated that exogenous activin stimulates chondrogenesis in chick 
mesenchyme cell cultures as evidenced by increased levels of Alcian blue staining for 
cartilage matrix proteoglycans (Jiang et al., 1993). Furthermore, the chondrogenic 
stimulatory effects of activin are also associated with increased expression of N-CAM 
and tenascin-C in prechondrogenic mesenchyme condensations (Jiang et al., 1993). 
 Insulin-like growth factor 1 (IGF-1) is also a positive regulator of 
chondrogenesis. Studies have shown that IGF-1, in combination with BMP-7 and 
Fibroblast growth factor 2 (FGF2), stimulates proteoglycan synthesis and chondrocyte 
proliferation in vitro (Patil et al., 2012).  In contrast, epidermal growth factor (EGF) is 
known to negatively regulate chondrogenesis in vitro, as addition of exogenous EGF 
to embryonic mesenchyme micromass cultures inhibits both condensation and overt 
chondrogenic differentiation as demonstrated by a reduction in Alcian blue staining 
for cartilage matrix proteoglycans (Yoon et al., 2000). 
 Fibroblast growth factors (FGFs) are responsible for mediating many of the 
epithelial-mesenchymal interactions involved in cellular differentiation within the 
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developing embryo (Greene and Pisano, 2004). Moreover, FGF family members have 
been implicated as both negative and positive regulators of chondrogenic 
differentiation. The various roles of FGFs and their receptors will be discussed in 
greater detail in the subsequent section. 
1.6 The Roles of FGFs and FGF Receptors in Chondrogenesis and 
Facial Development 
1.6.1 General characteristics of fibroblast growth factors 
 
 Fibroblast growth factors (FGFs) are a large family of evolutionarily 
conserved, structurally related growth factors which share a high affinity for heparin 
and heparan sulphate proteoglycans (Itoh and Ornitz, 2011). In vertebrates, at least 22 
FGFs have been identified (Itoh and Ornitz, 2004). FGF family members are further 
divided into at least 6 subfamilies on the basis of common biochemical and functional 
properties (Bottcher and Niehrs, 2005; Ornitz and Itoh, 2001; Ornitz and Marie, 
2002). FGFs have been implicated in a diverse array of cellular processes including 
proliferation, chemotaxis, migration, and differentiation (Francis-West et al., 1998).  
 Most FGFs contain amino-terminal secretion signal peptides and, as such, are 
present within the extracellular space. The majority of FGFs are secreted from cells 
via the endoplasmic reticulum-golgi apparatus pathway (Itoh and Ornitz, 2011). 
Interestingly, FGF1 and FGF2 lack N-terminal secretion signal peptides, and yet are 
still present within the extracellular space (Ornitz and Itoh, 2001). These FGFs may 
be released from damaged cells or by an endoplasmic reticulum-golgi apparatus 
independent exocytotic pathway (Nickel, 2010). Interestingly, FGFs 11 through 14 
are strictly located within intracellular compartments and function in a FGF receptor-
independent manner (Itoh and Ornitz, 2011). 
 FGFs found within the extracellular space mediate their respective biological 
responses by binding and activating FGF receptors (FGFRs). FGFs exist as monomers 
and their association with heparan sulphate proteoglycans enhances their ability to act 
as ligands for their cognate receptors (Itoh and Ornitz, 2004). Ligand binding to 
FGFRs induces homo- or heterodimerization of the extracellular immunoglobulin-like 
domains, leading to trans-autophosphorylation within the intracellular tyrosine kinase 
domain (Wilkie et al., 2002). Phosphorylation of specific tyrosine residues within the 
activation loop of the intracellular domain stimulates intrinsic catalytic activity of the 
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FGFRs and recruits members of downstream signalling pathways (McIntosh et al., 
2000). 
 Although there are least 22 members of the FGF family, only four distinct 
FGF receptors have been identified to date (Tsang and Dawid, 2004). All FGFRs are 
composed of three essential domains. The first domain, an extracellular ligand-
binding domain, consists of three distinct immunoglobulin-like domains. FGFRs also 
contain a single spanning transmembrane domain, and an intracellular domain which 
possesses tyrosine kinase activity (Jaye et al., 1992).  Importantly, alternative pre-
mRNA processing of the immunoglobulin-like domain of fgfr1, fgfr2, and fgfr3 gene 
transcripts produces two distinct isoforms characterized by specific patterns of ligand 
binding (Bottcher and Niehrs, 2005), and generates tissue-specific isoforms. For 
example, FGFrb isoforms are primarily expressed in the epithelia of a variety of 
embryonic tissues, whereas FGFRc isoforms predominate in mesenchyme adjacent to 
FGFRb expressing epithelia (Richman et al., 1997; Wilke et al., 1997). To date, 
alternative splicing of the immunoglobulin-like domains of fgfr4 mRNA has not been 
characterized (Loo et al., 2000).  
 Both FGFs and their cognate receptors are expressed in specific spatial and 
temporal patterns that serve to regulate FGF-signalling activity (McIntosh et al., 
2000). Moreover, the specific binding affinities of FGFs to their receptors mediates 
signal strength and determines which downstream signal transduction pathway is 
activated (Lunn et al., 2007). Association with heparan sulphate-containing 
proteoglycans located within the extracellular matrix also serves to regulate FGF 
signalling activity and specificity (Ornitz and Marie, 2002). This association is 
thought to mediate the action of FGFs through a number of different mechanisms. 
One proposed mechanism is that heparan sulphate proteoglycans bound to FGFs may 
restrict extracellular diffusion of FGFs, thereby localizing FGF signalling to restricted 
regions. Another proposed mechanism is that binding of heparan sulphate-containing 
proteoglycans to FGFs may promote formation of active FGF dimers or oligomers. In 
addition, association with heparan sulphate containing proteoglycans may stabilize 
the FGF-FGFR complex (Eswarakumar et al., 2005; Itoh and Ornitz, 2011).  
 The specific ligands responsible for FGFR activation during chondrogenesis in 
vivo have been difficult to identify, as signalling is dependent upon the temporal and 
spatial expression patterns of both ligand and receptors (Jiang et al., 1993; Miraoui 
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and Marie, 2010). Furthermore, Szebenyi et al. (1995) demonstrated changes in the 
expression patterns of FGFRs are intrinsic properties of differentiating chondrocytes 
(Szebenyi et al., 1995). For example, undifferentiated and proliferating mesenchyme 
cells predominately express FGFR1, whereas in condensations of prechondrogenic 
mesenchyme the predominant receptor is FGFR2. Fully differentiated chondrocytes 
primarily express FGFR3 (Szebenyi et al., 1995). 
 Within the developing embryo, FGFs and their receptors constitute a crucial 
signalling module, as loss of FGF-signalling results in embryonic lethality (Bottcher 
and Niehrs, 2005). FGFR activation can lead to activation of several distinct 
intracellular signal transduction cascades, such as the extracellular signal regulated 
kinase (ERK), signal transducer and activator of transcription 1 (STAT1), protein 
kinase C (PKC), and PLCγ-phosphatidylinositol 4,5-bisphosphate (PIP2) pathways 
(Debiais et al., 2001; Havens et al., 2006; Sahni et al., 2001). The large number of 
distinct intracellular signalling cascades activated by this family of ligands suggests 
the presence of multiple negative and positive regulators of FGF signalling. Indeed, 
members of the Sprouty and Mitogen-activated protein phosphatase families have 
been implicated as negative modulators, whereas ETS transcription factor family 
members (including Pea3 and Erm) have been implicated as positive regulators 
(Tsang and Dawid, 2004).  
1.6.2 FGF signalling in facial chondrogenesis 
 
 At least 6 FGFs (FGF1, -2, -4, -5, -8, and -12) are known to be expressed 
within the developing facial primordia along with all four types of FGFRs (FGFR1-4) 
(Francis-West et al., 1998). Utilizing in situ hybridization techniques with a probe 
antibody directed against FGF2, Richman et al. (1997) demonstrated that chick 
embryos of stages 15 through 24 ubiquitously express FGF2 throughout the 
mesenchyme and ectoderm of the frontonasal, mandibular, and maxillary facial 
primordia (Richman et al., 1997). At stages 24 and 28, the authors also demonstrated 
expression of FGF4 in the ectoderm at the medio-cranial surface of the mandibular 
arch and at the lateral portions of the ectoderm covering the nasal slits. Additionally, 
stage 20 chick embryos were found to express FGF8 throughout the ectoderm of the 
frontonasal primordia. This expression was downregulated at the center of the 
frontonasal primordia at stages 24 and 28, just prior the onset of chondrogenesis but 
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persisted in the lateral regions of the frontonasal primordia of stage 24 and stage 28 
chick embryos (Richman et al., 1997).    
1.7 MAPK Signal Transduction Pathways and their Roles in 
Chondrogenesis 
 
 Responsiveness of chondrogenic cells to both BMPs and FGFs requires 
activation of the highly conserved mitogen-activated protein kinase (MAPK) 
intracellular signalling cascades (Bobick and Kulyk, 2008). To date, four distinct 
MAPK families have been characterized: the extracellular signal regulated kinase 
(ERK1/2), p38-MAPK, c-Jun N-terminal kinase (JNK), and ERK5 (also known as big 
map kinase 1; BMK1) signal transduction pathways.  
 The common architecture of all MAPK signal transduction pathways is the 
presence of three or more sequentially acting protein-serine/threonine kinases. In its 
simplest form, the MAPK pathway involves the activation of a MAPK kinase kinase 
(MAPKK) via a dual phosphorylation event by a MAP kinase kinase kinase 
(MAPKKK). The phosphorylated MAPKK then phosphorylates a specific target 
MAPK (either ERK1/2, p38 MAPK, JNK, or ERK5). The activated MAPK then 
influences cell metabolism and gene expression via phosporylation induced activation 
or repression of a diverse array of various cytostolic and nuclear protein substrates 
(Widmann et al., 1999).   
 All MAPK signalling cascades are regulated to some extent by growth factors 
(Katz et al., 2007). MAPK signalling cascades have been shown to play diverse roles 
in the regulation of embryonic chondrogenesis (Bobick and Kulyk, 2004; Stanton et 
al., 2003). Stimulation of prechondrogenic mesenchyme cells by BMPs leads to p38-
MAPK activation and a positive effect on embryonic cartilage differentiation. In 
contrast, ERK1/2 activation in response to FGFs can either enhance or inhibit 
chondrogenesis depending on the anatomical location of the prechondrogenic 
mesenchyme cells.  The ERK1/2 pathway, of particular relevance to my research, will 
be discussed in greater detail in the subsequent section. 
1.7.1 Extracellular signal regulated kinase (ERK) signalling  
 The extracellular signal-regulated kinase (ERK1/2) signalling pathway, also 
known as the MEK/ERK pathway, is a critical signal transduction pathway involved 
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in proliferation, differentiation, and survival of eukaryotic cells (Bobick and Kulyk, 
2008).  A large number of mitogens, including growth factors and cytokines, and their 
cognate receptors are capable of inducing activation of the ERK pathway (reviewed in 
(Johnson and Lapadat, 2002). The ERK pathway is a critical downstream signalling 
pathway responsible for relaying extracellular FGF signals to the cell nucleus (Corson 
et al., 2003).  Moreover, during embryogenesis the sites of active dual phosphorylated 
ERK1/2 expression coincide closely with sites of FGF signalling. The association of 
FGF action with sites of ERK1/2 activity occurs in both chondrogenic (i.e. future 
skeletal elements) and non-chondrogenic regions (i.e. embryonic brain tissue) (Corson 
et al., 2003). 
 Consistent with the basic signalling architecture of all MAPK pathways, the 
ERK1/2 pathway includes three sequentially acting protein kinases. Located furthest 
upstream is Raf (a MAPKKK), followed by MEK (a MAPKK), and finally ERK1/2 (a 
MAPK). Although the molecular identities of the upstream stimuli may differ, the 
principal steps in the ERK1/2 signal transduction cascade remain the same. Upstream 
of the triple phospho-kinase relay system, the binding of a signalling ligand to its 
receptor induces phosphorylation of tyrosine residues located within the activation 
loop in the cytoplasmic tail of the receptor (Katz et al., 2007). Adaptor proteins, such 
as src-homology 2 domain containing transforming protein (SHC) and growth factor 
receptor-bound protein 2 (Grb2), link activated receptors to a guanine nucleotide 
exchange factor. These GTP/GDP exchange factors actively recruit small GTP 
binding proteins, such as Ras, to the receptor and phosphorylate them (Katz et al., 
2007). Ras, in turn, recruits members of the Raf family of serine threonine kinases to 
the receptor.  The Raf family (i.e. MAPKKKs) includes A-Raf, B-Raf, and c-Raf, 
which are activated by multiple phosphorylation and dephosphorylation events 
(Ramos, 2008). Activated Raf then dual phosphorylates specific serine residues 
within the activation loop of MEK1/2. Activated MEK1/2 in turn phosphorylates its 
specific downstream target, ERK1 and ERK2 (Ramos, 2008). Phosphorylation of 
ERK1/2 by MEK1/2 allows ERK to dissociate from the cytoplasmic anchored 
MEK/ERK complex (Adachi et al., 1999). Once dissociated, phosphorylated ERK1/2 
can activate more than 100 targets at various cellular locations (Ramos, 2008). 
Notably, dimerized ERK1/2 can be translocated to the nucleus, where it assists in 
regulation of gene expression through modification/phosphorylation of its nuclear 
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targets, such as Ets-like transcription factor 1 (ELK1) and members of the ETS family 
of transcription factors (Tsang and Dawid, 2004).  
1.7.2 ERK1/2 signalling in chondrogenesis 
 
 Much of what is known regarding the role of the ERK1/2 pathway in the 
regulation of cartilage differentiation has been elucidated through examinations of in 
vitro chondrogenesis of embryonic limb and facial mesenchyme. Current studies 
suggest that ligand bound FGF receptor kinases activate Ras, which in turn, activates 
the ERK signalling cascade (Dhillon and Kolch, 2002). Active phosphorylated 
ERK1/2 is abundant at sites of prospective chondrogenesis (Bobick and Kulyk, 2008; 
Corson et al., 2003). Moreover, ERK1/2 has been shown to function as either a 
negative or positive regulator of chondrogenesis depending on the embryonic origin 
of the prechondrogenic cells (e.g. limb bud vs. mandible) and their state of 
differentiation (Bobick, 2006b; Bobick et al., 2007; Bobick, 2006c).  
 A number of experimental observations suggest the ERK1/2 pathway 
functions as a negative regulator of cartilage differentiation in prechondrogenic 
mesenchyme within developing limb buds (Bobick et al., 2007). Endogenous levels of 
phosphorylated ERK (i.e. active ERK) progressively decline throughout the course of 
spontaneous chondrogenesis of chick limb bud mesenchyme in vitro (Chang et al., 
1998). Inhibition of MEK, the specific upstream activator of ERK1/2, within limb 
mesenchyme cultures increases production of both type II collagen and cartilage 
matrix proteoglycans (Bobick and Kulyk, 2004; Chang et al., 1998; Oh et al., 2000), 
and elevated expression of sox9, aggrecan, and type II collagen mRNAs (Bobick and 
Kulyk, 2004). Conversely, when a constitutively active MEK transgene was 
expressed within prechondrogenic limb mesenchyme cells, the activity of a sox9-
responsive collagen II enhancer-luciferase reporter gene was dramatically reduced 
(Bobick and Kulyk, 2004). 
 The MAPK/ERK signalling pathway may also be involved in the regulation of 
chondrogenesis of embryonic facial mesenchyme. An examination of spatial and 
temporal expression patterns of ERK signalling during mouse embryogenesis 
revealed prominent and sustained regions of ERK activation within the developing 
frontonasal process and pharyngeal arches (Corson et al., 2003). To define the roles of 
the MAPK/ERK pathway in facial chondrogenesis, Bobick and Kulyk (2006) 
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established micromass cultures of mesenchyme from embryonic chick facial 
primordia (Bobick, 2006b). In cultures of frontonasal mesenchyme isolated from 
stage 24/25 chick embryos, pharmacological inhibition of MEK increased 
chondrogenesis as evidenced by elevated levels of type II collagen, extracellular 
glycosaminoglycan accumulation, and expression of chondrogenic marker genes 
(sox9, col2a1, and aggrecan) (Bobick, 2006b). This suggests, that as in chick 
embryonic limb bud mesenchyme micromass cultures, the MEK/ERK pathway 
functions as a negative regulator of chondrogenesis in early stage frontonasal 
mesenchyme. Notably, however, in cultures of frontonasal mesenchyme isolated from 
stage 28/29 chick embryos, MEK inhibition decreased chondrogenesis, suggesting a 
stage-related shift in the chondrogenic regulation. Pharmacological inhibition of MEK 
in cultures of mandibular mesenchyme isolated from stage 24/25 chick embryos 
decreased chondrogenesis, as evidenced by a reduction in levels of type II collagen, 
extracellular matrix glycosaminoglycan accumulation, and expression of 
chondrogenic marker genes (Bobick, 2006b). This suggested that the ERK1/2 
signalling functions as a positive regulator of chondrocyte differentiation in 
mandibular mesenchyme cells. It was concluded that the ERK1/2 pathway plays both 
chondro-stimulatory and chondro-inhibitory roles in facial chondrogenesis, depending 
on the anatomical site from which the prechondrogenic mesenchyme cells originate as 
well as their specific stage of development.  
 Studies in which stage 24/25 chick frontonasal mesenchyme micromass 
cultures were treated with FGF2, -4, or -8 at concentrations of 10, 20, and 40 ng/ml 
found decreased cartilage matrix production and reduced expression of three cartilage 
specific genes: collagen type IIA, aggrecan, and sox9. Conversely, similar FGF 
treatment of chick stage 24/25 mandibular mesenchyme increased cartilage 
differentiation (Bobick et al., 2007). This study demonstrated a relationship between 
FGF signalling and the ERK1/2 pathway in facial chondrogenesis, since suppression 
of ERK activity by treatment with a pharmacological MEK inhibitor was able to 
block both the inhibitory effects of FGFs on frontonasal chondrogenesis and the 
stimulatory effects of FGFs on mandibular mesenchymal cells (Bobick et al., 2007). 
This indicates that FGF signalling can function in diverse or even opposite manners 
within distinct facial populations. Moreover, the response of facial mesenchyme cells 
to FGF was reported to be both stage and region specific (Bobick et al., 2007).  
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 Some members of the ETS superfamily of transcription factors have been 
implicated as downstream effectors of FGF and/or MAPK signalling (Wasylyk et al., 
1998). Thus, the various effects of FGFs on facial chondrogenesis are likely to be 
mediated, at least in part, through these ETS transcription factors. 
1.8 ETS Transcription Factors 
1.8.1 General characteristics of ETS transcription factors  
 The superfamily of ETS (E-twenty six) transcription factors consists of 
approximately 30 members (Wasylyk et al., 1998). They are evolutionarily conserved 
nuclear phosphoproteins involved in the regulation of cellular proliferation, 
differentiation and oncogenic transformation (Seth et al., 1992; Wasylyk et al., 1998). 
The characteristic feature of ETS transcription factors is the presence of a conserved 
85-amino acid DNA binding motif (ETS-DBM) that mediates binding to purine rich 
DNA sequences with a central GGAA/T core consensus and additional flanking 
sequences (Graves and Petersen, 1998). Structural composition and slight variations 
within the ETS-DBM allow further classification of ETS transcription factors into 
several subfamilies. Moreover, alteration of a single amino acid within the ETS 
domain can alter its DNA binding specificity (Oikawa and Yamada, 2003).   
  Several ETS family proteins are preferentially expressed in specific cell 
lineages, whereas others display ubiquitous expression (Oikawa and Yamada, 2003). 
For example, ternary complex factor ETS subfamily members, which includes Ets-
like transcription factor-1 (ELK-1), are expressed throughout a wide variety of tissues 
(Oikawa and Yamada, 2003), whereas E-74-like factor (ELF1) expression is restricted 
to hematopoietic cells and developing epithelial tissues, and epithelial specific ETS-1 
(ESE1) is exclusively expressed in epithelial cells (Oettgen et al., 1997).  
 ETS transcription factors influence gene expression by binding ETS-binding 
sites in the enhancers or promoters of target genes (Sharrocks, 2001). Specificity of 
target gene activation is mediated, in part, through interactions with other 
transcription factors and co-factors, which promotes or represses DNA binding 
(Oikawa and Yamada, 2003). For example, some ETS transcription factors associate 
with members of the Jun family of proteins. Members of these two families act 
cooperatively to bind DNA sequences, known as Ras-responsive elements, thereby 
enhancing transcriptional activation of target genes. Ras-responsive elements are 
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found within a variety of genes which are responsive to MAPK signalling (Oikawa 
and Yamada, 2003). 
 Evidence suggests ETS members are critical downstream effectors of MAPK 
signalling cascades (Wasylyk et al., 1998). Post-translational modification of ETS 
proteins, such as phosphorylation, regulates their downstream activity by altering 
DNA binding activity, affecting interactions with other co-regulators, and enhancing 
or repressing transcriptional activation capacities (Sharrocks, 2001). Phosphorylation 
of ETS proteins has also been shown to affect subcellular localization and/or protein 
stability (reviewed in (Oikawa and Yamada, 2003).   
 Importantly, transcription factors from at least 6 ETS subfamilies, including 
the Pea3 subfamily, have been directly implicated as downstream nuclear 
phosphorylation targets of the ERK signal transduction cascade (Wasylyk et al., 
1998).  
1.8.2 Pea3 subfamily of transcription factors 
 
 The polyoma enhancer activator-3 (Pea3) subfamily of ETS transcription 
factors is composed of three members: pea3, also known as ets-variant 4 (etv4); erm, 
also known as ets-variant 5 (etv5); and er81, also known as ets-variant 1 (etv1) 
(Sharrocks et al., 1997). Current evidence suggests that Pea3, Erm, and Er81 function 
primarily as transcriptional activators, and are capable of acting synergistically (de 
Launoit et al., 1997). In situ hybridization studies in mice and chick embryos have 
shown differential, although partial overlapping, patterns of pea3, erm, and er81 
mRNA expression in a number of developing organs (Chotteau-Lelievre et al., 1997; 
Lin et al., 1998). Furthermore, the sites of Pea3, Erm, and Er81 expression usually 
coincide with sites of endogenous FGF signalling (Raible and Brand, 2001; Roehl and 
Nusslein-Volhard, 2001).  
 Previous studies have also demonstrated FGF signalling is both necessary and 
sufficient for expression of pea3, erm, and er81 (Firnberg and Neubuser, 2002; Raible 
and Brand, 2001; Roehl and Nusslein-Volhard, 2001). Cellular levels of mRNA 
transcripts for pea3, erm, and er81 transcription factors are often upregulated in 
response to FGF signalling (Lunn et al., 2007; Roehl and Nusslein-Volhard, 2001). 
Moreover, Znosko et al. (2010) demonstrated that simultaneous knockdown of pea3, 
erm, and er81 expression in zebrafish embryos results in phenotypes reminiscent of 
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embryos deficient in FGF signalling (Znosko et al., 2010). Taken together, these 
findings suggest that Pea3 family of transcription factors are essential components of 
the FGF signalling pathway.  
1.9 Micromass Culture Model for Analysis of Mechanisms 
Regulating Chondrogenesis 
 
 Embryonic cartilage formation involves complex and intricate epithelial-
mesenchymal, cell-cell and cell-matrix interactions between multiple cell populations 
of different embryological origins. To clarify the mechanisms involved in embryonic 
cartilage differentiation, a simplified in vitro model, the “micromass” cell culture 
system, was developed in 1977 in the laboratory of Dr. Michael Solursh (Ahrens et 
al., 1977). The micromass system was initially employed for the experimental 
analysis of embryonic limb chondrogenesis (Ahrens et al., 1977).  
 To establish micromass cultures, a high-density cell suspension (typically 2 x 
107 cells/ml) is prepared from a prechondrogenic mesenchyme cell population. The 
prechondrogenic mesenchyme cells are usually isolated from limb buds dissected 
from stage 23 to stage 25 chick embryos, or from similarly staged rat and mice 
embryos. Micromass cultures can also be established from mesenchyme of the 
developing facial primordia (frontonasal, mandibular, maxillary, and hyoid). The 
dissociated cells are spotted at superconfluent density in 10 μl drops (2 x 105 cells per 
drop) onto tissue culture dishes. After a short period of time to allow for cellular 
attachment to the surface of the tissue culture dish, the cultures are flooded with 
serum-containing culture medium and are then incubated at 37°C in 5% CO2 for a 
period of 3 to 4 days (Daniels et al., 1996).  
 During this short incubation period, the mesenchyme cells spontaneously 
progress through the various stages of chondrogenic differentiation. The three-
dimensional, high density seeding of the prechondrogenic mesenchyme cells 
recapitulates the condensation/aggregation and differentiation events that occur 
during the initial stages of chondrogenesis in vivo (DeLise et al., 2000). Importantly, 
in vitro gene expression patterns throughout the chondrogenic differentiation process 
closely resemble those occurring in vivo (Kulyk et al., 2000). Specifically, 
mesenchyme cells within these aggregates begin to express high levels of type II 
collagen and aggrecan, and progressively accumulate Alcian-blue stainable cartilage 
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extracellular matrix. As such, the extent of chondrogenic differentiation can be 
measured by qualitative and quantitative assessment of levels of type II collagen, 
aggrecan, and Alcian blue stainable extracellular matrix.  
 Variations of the micromass culture system have been adopted in numerous 
laboratories for the analysis of cartilage differentiation. Several features make it an 
especially effective in vitro model for investigations of embryonic chondrogenesis. 
The progression of chondrogenic differentiation in micromass culture is rapid and 
closely parallels the principal phases of chondrogenic differentiation in vivo. Plating 
of cells in small 10 µl drops allows for the establishment of a large number of 
replicate high-density cell cultures from a relatively sparse amount of embryonic 
starting tissue. Micromass cultures are readily amenable to experimental 
manipulations, such as the addition of pharmacological inhibitors, growth factors, or 
siRNA constructs to the culture medium, and targeted gene transfections. Much of our 
current understanding of molecular events regulating in vivo cartilage differentiation 
were elucidated through in vitro studies of chondrogenesis in embryonic limb bud 
mesenchyme micromass cultures (Daniels et al., 1996). 
 In addition to its original application for studying embryonic limb 
chondrogenesis, the micromass method has been applied to the culture of embryonic 
facial mesenchyme cells, to the study of cartilage differentiation by multipotent 
mesenchymal stem cells derived from bone marrow or other adult tissues, for 
investigations into the regulation of chondrocyte hypertrophy and endochondral 
ossification, and for teratogenic drug screening.  In addition, micromass culture 
strategies are being adapted for cartilage tissue engineering applications (Bobick et 
al., 2009).   
1.10 Gene Expression Analysis using RT-qPCR 
 
 Since its invention nearly 30 years ago, the polymerase chain reaction (PCR) 
has made significant contributions to modern biology, biotechnology, medicine and 
agriculture (VanGuilder et al., 2008). Remarkably simple, yet extremely sensitive, 
PCR technology relies upon repeated heating and cooling cycles of a mixture of 
DNA, specific oligonucleotides, deoxynucleotriphosphates (dNTPs), and DNA 
polymerase, for exponential amplification of a specific target sequence (Chandler and 
Colitz, 2006). 
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 Real-Time quantitative PCR (RT-qPCR) has rapidly become the method of 
choice for analysis of relative gene expression (Nolan et al., 2006). Simultaneous 
amplification and quantification of specific nucleic acid sequences throughout the 
duration of the reaction are made possible with the inclusion of a single fluorescent 
reagent (DNA intercalating dye or dye-labelled probe) to the polymerase chain 
reaction. RT-qPCR has been reported to be more sensitive than RNase protection 
assays and RNA dot blot hybridizations, and has even been reported to be capable of 
detection of extremely low gene transcript expression (i.e. 5 gene transcripts). 
Moreover, RT-qPCR assays are capable of distinguishing even small differences (as 
low as 23%) in gene expression between samples (Wong and Medrano, 2005). Since 
RT-qPCR requires much less RNA template than other methodologies, it is also 
particularly useful in embryonic studies which are frequently limited by the nucleic 
acid content of the experimental samples (Wong and Medrano, 2005) 
 The conceptual and practical simplicity of RT-qPCR methodologies, lead to a 
dramatic increase in both the number of researchers using the technique and the 
number of papers citing the methodology (Pfaffl, 2010). However, critics argue that 
the increased use of RT-qPCR, combined with the nature of scientific journal 
publication itself, which traditionally only permits inclusion of minimal technical 
information, has resulted in a large number of unreliable and conflicting reports 
(Bustin, 2010). To improve upon the accuracy, reliability, and repeatability of RT-
qPCR experiments, the Minimum Information for Publication of Quantitative Real-
Time PCR (MIQE) guidelines were established (Bustin et al., 2009).  The MIQE 
guidelines attempt to standardize RT-qPCR experiments by addressing three key 
areas: (i) sample preparation, storage and quality, (ii) primer selection and design for 
both the reverse transcription and qPCR reaction, and finally (iii) statistical analysis 
and interpretation RT-qPCR data (Bustin et al., 2009). 
 According to the MIQE guidelines, sample acquisition and handling is the first 
source of potential experimental error, particularly in experiments designed to 
examine RNA expression profiles (Bustin et al., 2009). As such, the MIQE guidelines 
stipulate that all details pertaining to sample acquisition (i.e. type of starting tissue, 
time of storage before processing) must be reported along with detailed information 
regarding nucleic acid extraction methodology. Moreover, since comparisons across 
samples should involve the same amount of input RNA, it is crucial to accurately 
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quantify RNA. While a variety of different techniques are conventionally employed 
for total RNA quantification, the absolute measured values (in micrograms) 
frequently differ between methods (Bustin, 2005). As such, it is essential the same 
method of RNA quantification be used for all experimental samples and that the 
instrument used to perform the measurements is specified (Bustin et al., 2009).  
 The MIQE guidelines also requires performing quality control assessments of 
isolated nucleic acid sample integrity, as both the reverse transcription reaction and 
PCR amplification efficiencies can be dramatically affected by nucleic acid 
degradation (Bustin et al., 2009). Furthermore, partially degraded samples may reduce 
assay sensitivity such that expression ratios of low level transcripts (e.g. the mRNA of 
many transcription factors) do not accurately reflect their in vivo expression levels 
(Bustin et al., 2009). The MIQE guidelines state that simple measurement of a RNA 
sample’s A260/A280 ratio is insufficient for proper quality control, as the presence of 
contaminating genomic DNA or residual phenols can alter the ratio. As such, the 
authors of the MIQE guidelines recommend the use of either the Agilent 
Technologies BioAnalyzer instrument or BioRad’s Experion™ microfluidic 
electrophoresis system for assessment of nucleic acid sample integrity (Bustin et al., 
2009). 
 The second major source of variation in RT-qPCR experiments is the reverse 
transcription step (Bustin et al., 2009; Stahlberg et al., 2004). The MIQE guidelines 
require that all experimental conditions relating to cDNA synthesis be reported, and 
that such conditions are consistent across all compared samples (Bustin et al., 2009). 
In addition, all primer information (i.e. sequence, NCBI accession number, evidence 
of primer optimization) must be reported, as RT-qPCR amplification efficiencies are 
highly dependent upon primer design. The authors also strongly encourage all 
validated RT-qPCR primer information be submitted to open-access databases, such 
as RTprimerDB (http://medgen.ugent.be/rtprimerdb/), to improve standardization of 
RT-qPCR experiments across different laboratories (Bustin et al., 2009). 
 To date, while much effort has been directed at addressing the first two 
objectives of the MIQE guidelines (i.e. aspects related to experimental design), the 
methods employed for statistical analysis and interpretation of the data generated by 
RT-qPCR experiments remain highly variable (Pfaffl, 2010). Determination of 
relative gene expression levels in RT-qPCR experiments is based on the expression 
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ratio of a target gene versus an appropriate reference gene, that is assumed to be 
constitutively expressed. While this allows greater ease in analysis of gene expression 
trends, it is highly influenced by the choice of the reference gene and the 
normalization strategy (Pfaffl et al., 2002). There is also a need to determine 
amplification efficiency for each target and reference gene examined, as amplification 
efficiencies vary with the specific primer combination used (Bustin et al., 2009). 
 The Livak method (2-ΔΔC(T)) is the most commonly used mathematical 
model to calculate relative gene expression (Livak and Schmittgen, 2001; Pfaffl, 
2010). While this method allows for efficiency correction, it does not permit 
normalization of the data to multiple reference genes. Since reporting of RT-qPCR 
data involves relative expression ratios, which often have high variances, application 
of traditional parametric statistical methods has been suggested to be inappropriate as 
normal distribution of the data would not be expected (Pfaffl et al., 2002). To address 
the issues of uncertainty in measurement of expression ratios, the Relative Expression 
Software Tool (REST©) was developed (Pfaffl, 2001).  
 Utilizing randomization and bootstrapping techniques, REST© determines 
relative gene expression using the Pfaffl method: (Pfaffl et al., 2002) 
 
R = (Etarget)ΔCQ(control-sample)/(Ereference) ΔCQreference(control-sample) 
 
where R is the relative expression ratio, Etarget and Ereference are the PCR amplification 
efficiencies of the target and reference gene respectively, and ΔCQtarget(control-
sample) and ΔCQreference(control-sample) are the differences in quantification cycles 
between a control versus reference genes, respectively. A major advantage of the 
mathematical model used within REST© is that it makes no assumptions about the 
data distribution (i.e. does not assume a normal distribution). REST© graphically 
displays the data as box and whisker plots which provide a visual representation of 
variation for each gene.  
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2 RESEARCH OBJECTIVES AND HYPOTHESIS  
2.1 Experimental Rationale 
 
 Previous studies in our laboratory had shown that FGF treatment increased 
levels of dual phosphorylated (active) ERK in both frontonasal and mandibular 
mesenchyme cells, while inhibition of ERK signalling blocked the effects of FGFs in 
both cell populations (Bobick et al., 2007). Paradoxically, FGF had opposite effects 
on chondrogenic differentiation in the frontonasal and mandibular mesenchyme cell 
populations. Specifically, whereas FGF treatment inhibited cartilage differentiation in 
micromass cultures of frontonasal mesenchyme cells, it increased chondrogenesis in 
mandibular cultures (Bobick et al., 2007). This suggests that the mechanism 
responsible for the differential response of frontonasal and mandibular mesenchyme 
cells to FGF treatment lies at a point downstream of ERK activation. The 
transcription factors of the Pea 3 subfamily (Pea3, Erm, and Er81) are potential 
targets of ERK phosphorylation (O'Hagan et al., 1996), and have been shown to be 
crucial components of the downstream effector pathway through which FGFs 
influence gene expression (Raible and Brand, 2001). Moreover, embryonic tissues 
often differ in the specific combination of Pea3, Erm, and Er81 transcription factors 
that they express (Lunn et al., 2007), which might result in differential responses to 
upstream signals. The purpose of my M.Sc. project was to examine whether 
differential expression of Pea3, Erm, and Er81 transcription factors could underlie the 
opposing responses of embryonic frontonasal and mandibular mesenchyme cells to 
FGF treatment.  
2.2 Hypothesis 
Mesenchyme cells from the frontonasal and mandibular regions of the developing 
chick embryo face express the Pea3, Erm, and Er81 genes in distinct manners, which 
might account for their different responses to FGF signalling and ERK1/2 activation.  
2.3 Specific Objectives  
2.3.1 To test this hypothesis, the specific objectives of this study were:  
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1. To determine whether frontonasal and mandibular mesenchyme cells of the chick 
embryo exhibit distinct profiles of endogenous Pea3, Erm, and/or Er81 gene transcript 
expression. 
 
2. To determine whether there are differences in the extents to which treatment with 
exogenous FGF alters Pea3, Erm, and Er81 gene transcript levels in cultures of 
prechondrogenic mesenchyme cells isolated from the frontonasal and mandibular 
processes of the stage 24/25 and stage 28/29 chick embryo. 
 
3. To examine whether Pea3, Erm, and Er81 protein levels differ in embryonic 
frontonasal and mandibular mesenchyme cells. 
 
4. To compare the effects of FGF treatment on cartilage differentiation in cultures of 
facial mesenchyme cells isolated from the frontonasal and mandibular regions of the 
chick embryo.  
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3 MATERIALS AND METHODS  
3.1 Isolation of Frontonasal and Mandibular Mesenchyme and 
Preparation of Cultures 
3.1.1 Establishment of micromass and explant cultures 
 
 Fertilized Giant Cornish Cross chicken eggs were purchased from a 
commercial hatchery (Anstey Hatchery, Saskatoon, SK). Embryos were staged 
according to previously established methods (Hamburger and Hamilton, 1951). 
Frontonasal and mandibular facial processes of stage 24/25 and stage 28/29 chick 
embryos were excised and used for establishment of high density micromass as 
previously described (Kulyk et al., 1991; Kulyk and Reichert, 1992). Excised facial 
processes from similarly staged chick embryos were also used for establishment of 
explant cultures. 
3.1.2 Micromass cultures 
 
 To establish micromass cultures, excised facial processes were treated with 
0.8  U/ml dispase for 1 h, and all surface epithelial tissues (ectoderm and endoderm) 
were carefully removed. Isolated mesenchyme from each distinct facial process of 
approximately 3-5 dozen chick embryos were pooled, incubated for 20 min in 0.25% 
(v/v) trypsin, and dissociated into a suspension of 2 x 107 cells/ml in 
DMEM:F12/10% FBS medium (a 1:1 mixture of Dulbecco’s modified Eagle’s 
medium and Ham’s F12 medium supplemented with 10% [v/v] fetal bovine serum, 
2mM glutamine, and antibiotics [100μg/ml kanamycin, 100 U/ml penicillin G, 100 
μg/ml streptomycin, and 0.25 μg/ml amphotericin B]). High density micromass 
cultures were established by spotting 10 μl drops of cell suspension (2 x 105 cells per 
spot) onto 35 mm or 4-well NUNC tissue culture dishes. For the 4-well NUNC tissue 
culture dishes, a single 10 μl drop of cell suspension was dispensed into each 13 mm 
diameter well. For the 35 mm tissue culture dishes, approximately 5-10 cell 
suspension spots were plated onto each plate, unless otherwise indicated. Following a 
90 min incubation at 37°C/5% CO2 to permit cellular attachment, cultures were 
flooded with fresh media DMEM:F12/10% FBS medium and incubated for up to 3 
days.  
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3.1.3 Explant cultures  
 
 For analysis of frontonasal and mandibular mesenchyme ‘explant’ cultures, 
stage 24/25 facial processes were excised and the adherent epithelia were removed as 
described above. Eight to ten intact facial processes, which retained their native cell-
cell contacts, were cultured in 35 mm NUNC culture dishes in DMEM: F12/10% FBS 
medium at 37°C/5% CO2. Micromass and explant cultures were subsequently 
harvested for RNA analysis (RNA dot-blots, Northern blots and/or Real Time 
Quantitative PCR (RT-qPCR), Alcian blue histochemical staining, type II collagen 
immunohistochemistry, measurement of sulphated proteoglycan accumulation 
(DMMB assay), and/or Western blotting, following methods detailed below.   
3.1.4 FGF administration 
 
 To examine the effects of FGF on the RNA expression profiles of the Pea3 
group of transcription factors (pea3, erm, and er81), frontonasal and mandibular 
mesenchyme cultures were treated with exogenous FGF2 at a final concentration of 
20 ng/ml or 40 ng/ml (approximately 1.20 nM and 2.40 nM respectively), as 
previously reported (Bobick et al., 2007). FGF2 was omitted from parallel control 
cultures. Recombinant human FGF2 (basic FGF) was purchased from R & D Systems 
(Minneapolis, MN, USA; catalogue no. 233-FB-02533) or from Peprotech Canada 
(Dollard des Ormeaux, Quebec; catalogue no. 100-18B).  
 To minimize the negative effects of FGFs on cell viability, FGF2 was added to 
micromass cultures 12-13 h after the initial medium feed (see Figure 1). Micromass 
cultures were collected for RNA analysis 2 h after the administration of FGF2 unless 
otherwise indicated.  
 For explant cultures, the mesenchyme tissues isolated from stage 24/25 chick 
frontonasal and mandibular explant cultures were treated with recombinant human 
FGF2 (20 ng/ml) immediately after removal of all surface epithelia. Since the 
mesenchyme tissues in frontonasal and mandibular explants were not dissociated as 
with micromass cultures, a 12 h recovery period before administration of FGF2 was 
not considered necessary. Explant cultures were collected for RNA analysis 6 h after 
addition of FGF2 unless otherwise indicated. The FGF administration regimens for 
facial mesenchyme micromass cultures and explant cultures are summarized in Figure 
1. 
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Figure 1 Administration of Growth Factors Experimental Timeline. A timeline 
detailing the establishment of frontonasal (FN) and mandibular (MD) 
mesenchyme cultures, administration of FGF, and isolation of total cellular 
RNA.  (A) For micromass cultures, the facial mesenchyme cells were allowed to 
recover for a period of 12-13 h after tissue dissociation, cell plating and the initial 
medium feed prior to addition of exogenous FGF2. (B) For explant cultures, the intact 
facial mesenchyme tissues were treated with FGF2 immediately after excision and 
removal of adherent epithelia. For both micromass cultures and facial explants, 
control cultures were established in parallel except that FGF2 was omitted from the 
culture medium. (Note: timelines are not drawn to scale.) 
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3.2 RNA isolation & RNA integrity analysis  
 
 Stage 24/25 and stage 28/29 chick frontonasal and mandibular micromass and 
explant cultures were established in triplicate in 35 mm NUNC culture dishes as 
described above (for micromass cultures: ten to twelve 10 μl spots per plate; for 
explants: eight to ten intact facial processes per plate). Total RNA was isolated using 
an E.Z.N.A Total RNA kit (Omega, BioTek, Norcross, GA, USA) according to the 
manufacturer’s protocol. All RNA isolations included a 30 min on-column DNAse I 
digestion (Omega, BioTek, Norcross, GA, USA) as per the manufacturer’s directions. 
The concentration and purity of the isolated RNA were determined by measuring of 
total sample absorbance at A260 and the A260/A280 ratio using a Biorad SmartSpec 
UV/Vis spectrophotometer (Biorad, Hercules, CA, USA).  
 Representative samples of total RNA isolated from frontonasal and 
mandibular micromass and explant cultures were selected randomly and used for 
verification of RNA integrity prior to further downstream analysis. Overall integrity 
was assessed using a standard sensitivity RNA microfluidic chip (catalogue no. 700-
7110) on an Experion™ Automated Electrophoresis Station (Biorad, Hercules, CA, 
USA) according to the manufacturer’s protocol.  
3.3 RNA Dot-Blot and Northern Blot Methodology 
3.3.1 RNA dot blot analysis  
 
 For RNA dot blot analysis of pea3, er81, and erm gene transcript levels, total 
RNA was isolated from FGF2 treated and untreated stage 24/25 chick frontonasal and 
mandibular micromass cultures, and RNA concentration was determined by optical 
density measurements performed on a NanoVue spectrophotometer (GE Life Science, 
Fairfield, CT, USA). RNA dot-blot analysis was performed as described previously 
(Kosher et al., 1986a; Kosher et al., 1986b.; Kulyk et al., 2000).   
 Briefly, equivalent amounts of each RNA sample were spotted onto 0.45 μm 
MagnaGraph nylon transfer membrane (GE Water & Process Technologies, Trevose, 
PA, USA) using a BioDot apparatus (BioRad, Hercules, CA, USA). Nylon blots were 
subsequently baked in a vacuum oven at 80°C for 90 min, and pre-hybridized for 2-4 
h at 42°C in ULTRAHyb™ solution (Ambion, Life Technologies, Carlsbad, CA, 
USA). The nylon blots were then hybridized overnight in ULTRAHyb™ solution 
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containing [32P]-labelled single-stranded antisense cDNA probes specific for chicken 
pea3, erm, er81 and glyceraldhyde-3-phosphate dehydrogenase (gapdh) mRNAs. For 
detection of erm mRNA transcripts, hybridization was performed at 47°C.  For all 
other genes of interest, the hybridization was performed at a higher stringency 
temperature of 50°C. The [32P]-labelled single-stranded antisense cDNA probes were 
synthesized following a modification of the method of Konat (Konat, 1996) as 
detailed in Section 3.3.3 of Material & Methods below.  
 After overnight hybridization, the blots were washed in 2X SSC/0.1% (w/v) 
SDS (4 x 5 min/wash), followed by three 10 min washes in 0.1X SSC/0.1% SDS. All 
washes were performed at high stringency temperature (55°C) (Kosher et al., 1986a; 
Kosher et al., 1986b.; Kulyk et al., 2000). Blots were exposed to either Kodak 
BioMax AR (VWR, Radnor, PA, USA) or HyBlot CL™AR film (Denville Scientific, 
Metuchen, NJ, USA) with an intensifier screen at -80°C. When signal strength 
permitted, densiometric measurements at a wavelength of 540 nm on a Tecan SLT 
Spectra II spectrophotometric plate reader were used to quantify hybridization signals 
of exposed autoradiograph. The hybridization signals for pea3, erm, and er81 mRNA 
were normalized against signals for constitutively expressed gapdh transcripts.  
3.3.2 Northern blotting  
 
 Northern blots were used to verify the specifities of the [32P]-labelled cDNA 
probes employed in our RNA dot-blot analyses. For Northern blots, total RNA was 
isolated from whole heads of stage 24/25 chick embryos, then separated by 
electrophoresis on 1% (w/v) agarose gels containing 6% (w/v) formaldehyde in 1X 
3(n-morpholino)propane sulfonic acid (MOPS) buffer at 5 V/cm gel following the 
methods of Ausebel et al. (Ausubel, 1987). Following electrophoresis, the RNA was 
transferred by upward capillary action to MagnaGraph nylon membranes (GE Water 
& Process Technologies, Trevose, PA, USA). The membranes were baked at 80°C for 
90 min, prehybridized in ULTRAHyb™ solution, and hybridized to [32P]-labelled 
single-stranded cDNA probes in ULTRAhyb™ solution.  Prehybridization (at 42°C), 
hybridization  (47°-50°C) and subsequent washes (55°C) were performed under the 
same high stringency conditions described above for RNA dot blots (Materials & 
Methods Section 3.3.1). 
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3.3.3 Design and synthesis of [32P]-labelled single-stranded antisense cDNA 
probes for RNA dot blot & Northern blot assays  
 
 In order to generate the [32P]-labelled single-stranded antisense cDNA probes 
used in Northern blot and RNA dot blot analyses, we followed a modification of the 
LPCR (linear PCR) strategy of Konat (Konat, 1996). The LPCR method is essentially 
a modified PCR strategy in which a gene-specific DNA template is used in 
combination with a single reverse PCR primer and [32P]-dATP to generate labelled 
single-stranded antisense DNA probes complementary to a gene transcript of interest. 
Unlike conventional PCR in which the amplicons are double-stranded DNA 
fragments, the LPCR method generates only antisense amplicons that are 
complementary to the target mRNA sequence. This greatly increases the sensitivity of 
the resulting probe for detecting gene transcripts in Northern and RNA dot-blot 
applications (Konat, 1996). In our lab, we have refined the procedure further by 
employing strategically designed, custom synthesized single-stranded DNA templates 
in the LPCR reactions, as summarized below.   
 First, we used the NCBI nucleotide sequence database and NCBI/Primer-Blast 
software to identify partial cDNA sequences of 93 - 152 nucleotide length specific for 
the chicken pea3, erm, and er81 mRNA transcripts. Next, a single-stranded synthetic 
DNA corresponding to each sequence was custom synthesized (Integrated DNA 
Technologies, Coralville, IA, USA) to serve as a sense-strand template in subsequent 
LPCR reactions. In addition, a reverse LPCR primer (20-23 nucleotide length) 
complementary to the 3’-end of each synthetic DNA template was synthesized. 
(Detailed sequence information for all LPCR templates and primers that were used is 
provided in Table 1).  
 The [32P]-dATP labelled single-stranded antisense cDNA probes used in our 
Northern blot and RNA dot blot analyses were generated using a Strip-EZ® PCR 
labelling kit (Ambion, Austin, TX, USA) following the manufacturer’s linear 
amplification protocol. The reaction mixtures were subjected to 30 cycles at the 
following parameters: 94°C for 2 min; 55°C for 2 min, and 72°C for 5 min in an MJ 
Research Thermocycler (MJ Research, Waltham, MA, USA). The reaction products 
were passed through a Sephadex G-50 spin column packed in a Costar® spin-X 0.2 
μm micropore filtration unit (Sigma, St Louis, MO, USA) to remove unincorporated 
label, and then used as probes in Northern and RNA dot blot procedures.  
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Table 1  Primer & Template Sequences Used to Generate Gene-Specific Probes 
for Northern and RNA dot blot analyses.   
 
 
Note: The pea3, erm and er81 templates were custom synthesized single-stranded 
DNA sequences. For gapdh, the template used was a previously cloned double-
stranded partial cDNA. Two different template/primer sets were used for erm 
transcript detection. The erm A template/primer combination was used in preliminary 
RNA dot-blot experiments (see legend for Figure 4). Due to problems with probe 
labelling, however, a new template/primer combination (erm B) was employed for all 
subsequent RNA dot blot and Northern blot experiments. 
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3.4 RT-qPCR Analysis Methodology 
3.4.1 RT-qPCR primer design 
 
 For RT-qPCR analyses of pea3, er81, erm, gapdh and RNA polymerase II b 
(RNA pol II b) mRNA levels, gene-specific primer pairs were designed using 
sequence information from the NCBI nucleotide sequence database and the Gene 
Ensembl database (European Molecular Biology Laboratory; European 
Bioinformatics Institute), with the assistance of IDT Oligo-analyzer, NCBI Primer 
Blast and NCBI Blast software programs. All qPCR primers were designed in 
accordance with published guidelines (Bustin et al., 2009). Wherever possible, the 
forward qPCR primer and/or reverse qPCR primer were designed so as to span 
putative exon/intron junctions, in order to minimize the possibility of amplifying 
genomic DNA sequences in RT-qPCR reactions. Sequence information for all qPCR 
primers employed is provided in Table 2. 
3.4.2 Reverse transcription (cDNA synthesis)  
 
 First strand cDNA synthesis from total RNA isolated from chick frontonasal 
and mandibular mesenchyme cultures was performed using the QuantiTect™ Reverse 
Transcription Kit (Qiagen, Valencia, CA, USA) which includes a DNAse I digestion 
step, following the manufacturer’s protocol. For each reverse transcription reaction, 1 
μg of total RNA was used. 
3.4.3 qPCR reactions  
 
 The effects of FGF treatment on pea3, erm, and er81 gene transcript levels 
were determined in micromass and explant cultures of stage 24/25 frontonasal and 
mandibular mesenchyme by RT-qPCR analysis, as detailed below. Gene expression 
was quantified using chicken-specific qPCR primers and the Maxima® SYBR Green 
(Fermentas, ThermoScientific, Waltham, MA, USA) reagent system according to 
manufacturer’s protocols. Amplification reactions were performed on an MJ Mini™ 
Thermal Cycler equipped with a MiniOpticon™ Real-Time PCR detection system 
(BioRad, Hercules, CA, USA). Gene expression of two reference genes, gapdh and 
RNA pol II b, was also analyzed to enable normalization of the pea3, erm, and er81 
qPCR data in accordance with the MIQE guidelines (Bustin et al., 2009). To prevent  
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Table 2 Primers used for RT-qPCR analysis. 
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contamination of qPCR reactions, all reactions were prepared in a biological safety 
cabinet decontaminated with a 10% (v/v) bleach solution followed by a 30 min UV 
irradiation cycle. In addition, 1 μl of uracil-DNA glycosylase (UDG; 
ThermoScientific, Waltham, MA, USA) was included in each reaction to prevent 
carry-over contamination (Longo et al., 1990). 
 Thermocycling parameters were as follows: 50°C for 2 min (UDG pre-
treatment), 95°C for 10 min (initial denaturation), and 40 cycles of 95°C for 15 s 
(denaturation), 55°C (pea3)/61°C(erm)/58°C (er81)/60°C (gapdh and RNA pol II b) 
for 30 s (optimal annealing temperatures), and 72°C for 30 s (extension). Melt curve 
analysis was performed immediately upon the completion of each qPCR reaction to 
ensure amplification of a single gene product.  
 For each experiment, RNA was isolated from three replicate cultures for each 
different treatment group (i.e. 3 biological replicates per treatment, (n = 3); see Figure 
2). Each RT-qPCR experiment was repeated a total of three or four times (i.e. 3-4 
independent experimental repeats x 3 biological replicates per treatment per 
experiment; therefore n = 9 or 12).  
 The mean Cq value for each biological replicate was used for relative gene 
expression analysis using the Relative Expression Software Tool (REST©) (Qiagen, 
Valencia, CA, USA) (Pfaffl et al., 2002). For all RT-qPCR experiments involving 
micromass cultures, two additional independent qPCR experiments were performed, 
and the resulting data from all experiments pooled for final REST analysis (n = 9). 
For RT-qPCR gene expression analysis of stage 24/25 frontonasal and mandibular 
explants, three additional independent qPCR experiments were performed (n = 12).  
3.4.4 qPCR primer validation 
 
 To determine the optimal annealing temperature for each gene specific primer 
pair, cDNA generated from the RNA of stage 24/25 chick embryo heads was used in 
12-step temperature gradient reactions (covering a temperature range of 52°C-64°C) 
using the Maxima® SYBR Green RT-qPCR reagent system (Fermentas, 
ThermoScientific, Waltham, MA, USA) according to the manufacturer’s protocol on 
a MJ Mini Thermal Cycler/MiniOpticon™ instrument (Biorad, Hercules, CA, USA). 
The annealing temperature that resulted in the earliest quantification cycle (i.e. lowest 
Cq value) and highest melt peak for each gene specific primer pair was used for all  
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Figure 2 Schematic diagram representing the experimental design for Real-Time 
Quantitative Polymerase Chain Reaction Experiments. This schematic represents 
the experimental design of a single RT-qPCR experiment. Each individual RT-qPCR 
experiment resulted in an n=3 per treatment group. Pooled data from 3 or 4 
independent experiments increased the n number for final REST analysis to n=9 for 
micromass cultures, and n=12 for explant cultures. FN = frontonasal processes 
(pooled); MD = mandibular processes (pooled); Cq = quantification cycle as 
determined by RT-qPCR. 
  41 
 
subsequent qPCR reactions. To ensure each primer pair amplified only its specific 
target gene sequence, qPCR temperature gradient products were separated by 
electrophoresis on a 15% (w/v) polyacrylamide gel using standard protocols. In 
addition, a melt-curve analysis was performed immediately upon completion of the 
RT-qPCR reaction to ensure amplification of a single gene product. Reactions 
containing no cDNA (i.e. no template controls; NTCs) were run alongside samples to 
verify the absence of primer-dimer formation or contamination of the reagents. 
Additionally, to ensure adequate removal of genomic DNA (gDNA), six randomly 
selected samples were used as no reverse transcription controls (NRTs).   
3.4.5 Determination of qPCR amplification efficiencies  
 
 Amplification efficiencies between gene specific primer pairs commonly 
differ as a result of variations in primer annealing, G-C content and length of 
sequence amplified. Therefore, standard curves for each target gene (pea3, erm, and 
er81) and reference genes (gapdh and RNA pol II b) were prepared in triplicate. 
Standard curves for gapdh and RNA pol II b were created by a 10-fold serial dilution 
(10x, 1x, 1/10x, 1/100x, 1/1000x, 1/10000x, 1/100000x) of cDNA generated from 
isolated RNA from heads of stage 24/25 chick embryos. Standard curves for pea3, 
erm, and er81 were prepared by a 5-fold serial dilution of cDNA generated from 
isolated RNA from heads of stage 24/25 chick embryos (5x, 1x, 1/5x, 1/25x, 1/125x).  
3.4.6 Statistical analysis of qPCR data  
 
 Relative gene expression of each target gene (pea3, erm, and er81) was 
normalized to both gapdh and RNA pol II b in compliance with MIQE guidelines 
(Bustin et al., 2009). All comparisons were performed using the Relative Expression 
Software Tool (REST©; Qiagen, Valencia, CA, USA), which employs the Pfaffl 
method for determination of relative gene expression (Pfaffl, 2001; Pfaffl et al., 
2002). The data resulting from all REST™ comparisons are displayed graphically as 
box-and-whisker plots. For final REST™ analysis, data from three independent 
micromass culture experiments were pooled (n= 9). Data from four independent 
explant culture experiments were pooled for final REST™ analysis (n=12).  
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3.5 Determination of Chondrogenic Differentiation 
3.5.1 Alcian blue histochemical detection of sulfated proteogylycans 
 
 Alcian blue histochemical staining was used to examine sulfated cartilage 
matrix proteoglycan accumulation in stage 24/25 and stage 28/29 micromass cultures. 
Micromass cultures were established and treated with FGF2 as described in Materials 
& Methods Sections 3.1.2 and 3.2.4. FGF treated and untreated (control) frontonasal 
and mandibular micromass cultures were collected after 2 or 3 days, respectively, of 
incubation at 37°C/5% CO2. Cultures were then stained overnight with 0.2% (w/v) 
Alcian blue 8 GX (Fluka, Sigma, St Louis, MO, USA), pH 1.0 (Chang et al., 1998; 
Hassell and Horigan, 1982). After staining, cultures were rinsed once with distilled 
water to remove unbound dye. Representative Alcian blue stained cultures were air 
dried and photographed.  
 For other cultures, the bound Alcian blue stain was eluted and quantified 
spectrophotmetrically as previously described (Chang et al., 1998; Hassell and 
Horigan, 1982). Briefly, 4 M guanidine hydrochloride was added to each stained 
culture, the plates were sealed with parafilm, then incubated overnight at room 
temperature. Equal volumes of the eluted dye solution were transferred to a 96-well 
microtiter plate and absorbance of each sample was measured using a Tecan SLT 
Spectra II plate reader at a wavelength of 600 nm. For some experiments, absorbance 
readings were then normalized against the average DNA content of replicate parallel 
cultures. A fluorescence assay (Labarca and Paigen, 1980) was used to determine 
total DNA of micromass cultures, as detailed below. 
3.5.2 Hoechst 33258 DNA fluorescence assay 
 
 The total DNA content of frontonasal and mandibular facial mesenchyme 
micromass cultures was quantified using a Hoechst 33258 (Sigma, St Louis, MO, 
USA) fluorescence assay (Labarca and Paigen, 1980). Each micromass culture was 
sonicated in 350 μl Hank’s buffered saline solution (HBS). Then a 100 μl volume of 
each sonicate was combined with 100 μl of 4 μg/ml Hoechst dye, and 200 μl assay 
buffer (0.1 M NaPO4, 4 M NaCl, pH 7.4). Aliquots (200 μl) of each sample were 
transferred to individual wells of a black 96-well microtiter plate, and read on a 
fluorometer (Fluorolite 1000, Dynex, Richfield, MN, USA) at an excitation 
wavelength of 365 nm and an emission wavelength of 458 nm. A series of chicken 
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DNA (Pharmacia, Piscataway, NJ, USA) standards (0.25, 0.50, 1, 2, and 4 μg total 
DNA) was prepared in a similar manner and run alongside cell culture sonicate 
samples. The DNA content of each sample was determined from a standard curve and 
quantified by linear regression analysis using InStat 2.01 (GraphPad) software. The 
resulting DNA values were used to normalize densitometric data of eluted Alcian blue 
eluted from frontonasal and mandibular mesenchyme micromass cultures.  
3.5.3 Quantification of sulfated glycosaminoglycan accumulation   
 
 A 1,9-dimethylmethylene blue (DMMB) assay, based on the methods of 
(Barbosa et al., 2003), was used for quantification of total sulphated GAGs in the cell 
layer and medium fractions of stage 24/25 and stage 28/29 frontonasal and 
mandibular micromass cultures. To prepare the DMMB stock solution, 16 mg of 1,9-
dimethylmethylene blue dye was dissolved in 25 ml ethanol and filtered through 
standard filter paper. The DMMB working solution was prepared in several steps to 
prevent the DDMB dye from precipitating out of solution. First, 35 ml of distilled 
water, 8.3 ml of 6 M guanidine hydrochloride, 0.5 g sodium formate, and 0.5 ml of 
98% (v/v) formic acid was mixed, and brought to a final volume of 50 ml in distilled 
water (solution A).  Solution B was prepared by adding 25 ml of solution A to 6.25 ml 
absolute ethanol. The solution was then brought to a final volume of 125 ml in 
distilled water. To prepare solution C, 25 ml of solution B was added to 6.25 ml 
DMMB stock solution, mixed quickly and brought to a final volume of 125 ml in 
distilled water. To prepare the final DMMB working solution, equal volumes of 
solutions B and C were combined and stored in the dark at room temperature. DMMB 
Wash Solution was prepared by the addition of 35 ml of distilled water, 8.33 ml of 6 
M guanidine hydrochloride, 0.5 mg sodium formate, and 0.5 ml 98% (v/v) formic 
acid in a final volume of 50 ml in distilled water. To this solution, 12.5 ml of 95% 
(v/v) ethanol and 187 ml of distilled water was added. DMMB Decomplexing 
Solution was prepared by combining, 134 ml 6 M guanidine hydrochloride, 40 ml 
0.25 M sodium acetate solution [pH 6.8], 20 ml 1-propanol, and 6 ml of distilled 
water. 
 To perform the DMMB assay, the medium was removed from each facial 
mesenchyme micromass culture and transferred to a microcentrifuge tube. The 
micromass cell layer was detached from the culture dish, collected in 350 μl Hank’s 
buffered saline solution (HBSS), and transferred to separate microcentrifuge tubes. A 
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1μl volume of 5 mg/ml Proteinase K (Invitrogen Life Technologies, Carlsbad, CA, 
USA) solution (20 mg proteinase K in 4 ml of 10mM Tris HCl [pH 7.5], 20mM CaCl2 
(Sigma, St Louis, MO, USA), and 50% glycerol) was added to both the medium and 
cell layer fractions. Following overnight incubation at 50°C, all samples were heated 
for 10 min at 90°C. Cell layer fractions were homogenized by repeated pipetting and 
a 100 μl aliquot was withdrawn for determination of total DNA content by the 
Hoechst 33258 fluorescence assay as described in Materials & Methods Section 3.5.2. 
The remainder of the cell layer homogenate was passed through a Millipore Ultrafree 
spin-filter (Millipore, Billerica, MA, USA) to remove DNA and cellular debris. A 
series of chondroitin sulphate standards (0 μg/100 μl to 8 μg/100 μl) was prepared 
alongside the cellular and medium fraction samples. To 100 μl of each cell layer, 
medium, or chondroitin sulphate standard, 1 ml of DMMB working solution was 
added. The samples were vortexed vigorously for 30 min, then centrifuged at 16,000g 
for 15 min at 4 °C. Following careful aspiration of the supernatant, 1 ml of DMMB 
Wash Solution was added to each sample. The samples were re-centrifuged (16,000g, 
15 min, 4°C), and the supernatant removed by aspiration. To each pelleted insoluble 
GAG/DMMB complex, 1 ml of Decomplexing Solution was added. Samples were 
vortexed vigorously for 20 min, and 200 μl aliquots of each sample were transferred 
to individual wells of a 96-well transparent microtiter plate. A Tecan SLT Spectra II 
spectrophotometric plate reader was used to measure absorbance at a wavelength of 
650 nm. The concentration of total sulfated GAGs in each cell layer and medium 
sample was then determined from the linear regression equation of the chondroitin 
sulphate standard curve using InStat 2.01 software.  
3.5.4 Type II collagen immunostaining  
 
 Accumulation of type II collagen in stage 24/25 and stage 28/29 frontonasal 
and mandibular micromass cultures was detected by immunocytochemical staining 
with a monoclonal antibody against chicken type II collagen as previously described 
(Bobick and Kulyk, 2004). Briefly, frontonasal and mandibular micromass cultures 
were harvested after 2 or 3 days of incubation, washed twice in phosphate buffered 
saline (PBS) Tween-20 (PBST) (1 x 1 min; 1 x 5 min), and fixed for 30 min in 95% 
(v/v) ethanol containing 2% (v/v) acetic acid. After fixation, the cultures were rinsed 
in 70% (v/v) ethanol 3 times (1 x 1 min; 2 x 5 min/wash), and stored in 70% (v/v) 
ethanol for up to 2 weeks. Micromass cultures were rehydrated by rinsing for 5 min 
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each in decreasing ethanol concentrations (70%, 50%, 25%, 0% (v/v) ethanol in 
distilled water) and post-fixed for 1 h in 4% (v/v) formalin/PBST. Following post-
fixation, cultures were washed (3 x 5 min) in PBST, and blocked for 90 min in 5% 
sheep serum (v/v) (Sigma, St Louis, MO, USA)/PBST. Micromass cultures were 
incubated for 1 h in a 1:50 dilution of chicken collagen II monoclonal antibody II-
II6B3 hybridoma supernatant (Developmental Studies Hybridoma Bank, University 
of Iowa) in 5% (v/v) sheep serum/PBST. Following primary antibody incubation, 
micromass cultures were washed (4 x 5 min/wash) in PBST and incubated for 1 h in a 
1:250 dilution of alkaline phosphatase-conjugated goat anti-mouse IgG antibody 
(Sigma, St Louis, MO, USA) in 5% (v/v) sheep serum/PBST. Cultures were 
subsequently washed (3 x 10 min/wash) in PBST containing 0.05% levamisole and 
then washed (2 x 15 min/wash) in NTMT (100 mM Tris HCl, pH 9.5, 50 mM MgCl2, 
100 mM NaCl, 0.1% (v/v) Triton X-100, 0.05% (w/v) levamisole). Micromass 
cultures were incubated for 30-60 min in nitroblue tetrazolium chloride (0.34 mg/ml) 
and 5-bromo-4-chloro-2-indolylphosphate (0.175 mg/ml) dissolved in NTMT to 
permit colour development. Following development, cultures were rinsed 3 times in 
PBST, then stored in CMFET solution (0.137 M NaCl, 0.003 M KCl, 0.008 Na2HPO4, 
0.0015 M KH2PO4, 0.7 mM EDTA, 0.1% [v/v] Tween-20) at 4°C prior to 
photographing.  
3.6 Western Blot Protein Analyses 
3.6.1 Protein quantification 
  
 The method of Minamide and Bamburg were used to determine cellular 
protein content (Minamide and Bamburg, 1990) of samples used for Western blot 
analysis. This filter paper based adaptation of the Bradford protein-dye binding assay 
(Bradford, 1976), has several advantages over the original Bradford method, 
including increased sensitivity and a resistance to interference by reagents used in cell 
lysis buffers, such as sodium dodecyl sulphate (SDS) and bromophenol blue.  
 In brief, sonicated cell/tissue homogenates (see below) were spotted in aliquot 
volumes ranging between 0.625 μl and 25 μl onto individual squares of a 1.5 cm x 1.5 
cm grid drawn on Whatman No.1 filter paper. A series of protein standards (a 1:3 
mixture of BSA and ϒ-globulin; 0 to 20 μg total protein per square) were spotted 
alongside samples of unknown protein concentration. All samples were spotted in 
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triplicate. Spotted filter paper was air-dried, rinsed in absolute methanol for 
approximately 1 min to remove non-proteinaceous materials, and re-dried. The filter 
paper was washed in 0.5% (w/v) Coomasie brilliant blue G in 7% (v/v) acetic acid for 
30 min at room temperature with gentle agitation, then washed in 7% acetic acid (v/v) 
to reduce background staining. After air-drying, individual filter paper squares were 
cut out and placed in microcentrifuge tubes containing 1 ml of extraction buffer (66% 
(v/v) methanol, 1% (v/v) ammonium hydroxide, and 33% (v/v) distilled water). A 300 
μl aliquot of each sample was transferred to a 96-well microtiter plate and the 
absorbance of each sample at 600 nm wavelength was read on a Tecan SLT Spectra II 
plate reader. A standard curve was generated by plotting the absorbance values of the 
protein standards against their known protein content. The linear regression equation 
of the standard curve was then used to determine cellular protein content for each 
experimental sample.  
3.6.2 Western blot analysis  
 
 For Western blot protein analysis, stage 24/25 chick frontonasal and 
mandibular micromass cultures were spotted on 35 mm NUNC tissue culture plates 
(10 - 12 spots per dish) and treated with FGF2 as described previously. Micromass 
cultures were harvested at representative time points (2, 6, 12, 24, and 48 h following 
FGF2 treatment), and cells from each individual culture plate were homogenized in 
250 μl lysis buffer (Puck’s saline containing protease inhibitors (4 mM 
phenylmethylsulfonyl fluoride; PMSF) and Sigma protease inhibitor cocktail P8340 
(used at 2X final concentration; Sigma, St Louis, MO, USA). A 50 μl volume of 1 M 
dithioreitol (DTT) and 50 μl of 6X Laemmli SDS-sample reducing buffer (BioPLUS 
Fine Research Chemicals, distributed by Cedarlane, Burlington, ON, CA) were added 
to each lysate. The samples were sonicated, subjected to denaturing gel 
electrophoresis and protein transfer to NitroPure supported nitrocellulose (GE Water 
& Process Technologies, Trevose, PA, USA) using the Biorad Protean II Minigel 
apparatus (Biorad, Hercules, CA, USA) according to standard protocols. Proteins 
were separated on 12.5% (w/v) polyacrylamide gels containing 0.1% (w/v) SDS. 
Following overnight wet transfer at 4°C onto nitrocellulose membranes, blots were air 
dried and blocked in 10% (w/v) blotting-grade non-fat dry milk (BioRad, Hercules, 
CA, USA)/PBST for 3 h. Primary and secondary antibodies were diluted in 2% (w/v) 
blotting-grade non-fat dry milk in PBST. Total Pea3 was detected using a 1:5000 
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dilution of polyclonal antibody against mouse Pea3 protein (Abcam, Cambridge, MA, 
USA; catalogue no. ab101455). Total Er81 was detected using a 1:2500 dilution of 
monoclonal hybridoma supernatant 72.5B10 against chicken Er81 (Developmental 
Studies Hybridoma Bank, University of Iowa). GAPDH was detected using a 1:10000 
dilution of anti-GAPDH antibody (Calbiochem, Millipore, Billerica, MA, USA; 
catalogue no. CB1001). Attempts to detect total Erm using a rabbit polyclonal 
antibody (Aviva Systems Biology, San Diego, CA, USA; catalogue no. 
ARP38468_P050) were unsuccessful as developed blots exhibited non-specific 
multiple banding patterns. All primary antibody incubations were carried out 
overnight at 4°C. Following primary antibody incubation, nitrocellulose blots were 
washed (3 x 1 min; 2 x 5 min) in PBST, and incubated at room temperature for 90 
min in the appropriate anti-mouse or anti-rabbit horseradish peroxidase-conjugated 
secondary antibodies (Calbiochem, Millipore, Billerica, MA, USA) at the following 
concentrations: 1:10000 (for Pea3 detection); 1:5000 (for Er81); and 1:100,000 (for 
GAPDH). Blots were subsequently washed in PBST (1 x 1 min; 3 x 5 min). Signal 
detection was performed using the SuperSignal West Femto Chemiluminescent 
Substrate (ThermoScientific, Waltham, MA, USA) as per the manufacturer’s 
instructions.  The chemiluminescence signals were captured using the Versadoc™ 
(Biorad, Hercules, CA, USA) imaging system. 
3.7 Statistical analysis  
 Statistical analysis of data pertaining to Alcian blue staining, cellular DNA 
measurements, and sulfated GAG accumulation was performed by a one-way analysis 
of variance (ANOVA) with the Bonferroni multiple comparison post-hoc test using 
InStat 2.01 software, and graphed with Microsoft® Excel® 2008. All RT-qPCR gene 
expression comparisons were performed using REST© software as described in 
Material & Methods Section 3.4.6. P-values less than 0.05 were considered 
statistically significant.  
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4 RESULTS 
4.1 Initial Investigation of pea3, erm, and er81 mRNA expression  
4.1.1 Confirmation of cDNA probe specifities by Northern blot analysis    
 In initial experiments, conventional methods of Northern blot hybridization 
and RNA dot blot hybridization were used to examine expression of the pea3, erm, 
and er81 gene transcripts in chick embryo facial mesenchyme tissues. Antisense 
cDNA probes for each gene were generated from custom synthesized synthetic DNA 
templates as described in Material & Methods Section 3.3.3. 
 Northern blot analysis was performed to determine the specificity of the 
cDNA probes for their mRNA respective targets (pea3, er81, and erm). Since the 
mRNA of Pea3 transcription factors is expressed in relatively high levels within the 
developing brains of chick embryos (Lunn et al., 2007), total RNA was isolated from 
freshly excised whole heads of stage 24/25 chick embryos. Equivalent amounts (5 μg) 
of total RNA were separated by agarose gel electrophoresis and blotted by upward 
capillary transfer onto nylon membrane. The membranes were hybridized to 32P-
labelled antisense cDNA probes and washed under high stringency conditions 
following standard protocols. 
 The pea3 cDNA probe specifically recognized a single transcript of 
approximately 3.9 kb (Figure 3A). A solitary transcript of approximately 3.45 kb was 
recognized by the erm cDNA probe (Figure 3 B). The er81 cDNA probe specifically 
recognized two transcripts of approximately 3.7 kb and 3.2 kb (Figure 3C), which is 
consistent with a previous report that there are two alternatively spliced er81 mRNA 
isoforms in the mouse and human (Coutte et al., 1999).  Consistent with previously 
published results, the gapdh cDNA probe specifically recognized a single transcript of 
approximately 1.5 kb (Figure 3D) (Bobick et al., 2007; Milner et al., 1983). 
4.1.2 Preliminary RNA dot blot analysis   
 RNA dot-blot analysis was used to examine the effects of FGFs on pea3, erm, 
and er81 mRNA expression profiles during chondrogenesis. Micromass cultures of 
stage 24/25 frontonasal mesenchyme and stage 24/25 mandibular mesenchyme cells 
were cultured for 2, 5, 12, or 20 h in control DMEM:F12/10% FBS medium or in  
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Figure 3 Northern blot analysis of pea3, erm, er81, and gapdh gene cDNA probe 
specifities. Total RNA was isolated from the whole heads of stage 24/25 chick 
embryos and processed for Northern blot analysis. The pea3 (A) and erm (B) cDNA 
probes each recognized a single mRNA transcript of approximately 3.9 kb and 3.45 
kb length, respectively. The probe for er81 (C) recognized two gene transcripts of 
approximately 3.2 kb and 3.7 kb. The cDNA probe for gapdh (D) specifically 
recognized a probe  of approximately 1.5 kb.   
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FGF supplemented (20ng/ml) DMEM:F12/10% FBS medium. 
  In both stage 24/25 frontonasal and mandibular mesenchyme micromass 
cultures, FGF2 treatment elevated expression of pea3 mRNA in comparison to 
untreated controls at all examined time points (2, 5, 12, and 20 h) (Figure 4 A). 
Similarly, FGF2 also elevated expression of er81 mRNA transcripts at all time points 
in stage 24/25 frontonasal and mandibular mesenchyme micromass cultures relative 
to untreated controls (Figure 4B). This suggests FGF2 upregulates pea3 and er81 in 
both frontonasal and mandibular mesenchyme micromass cultures. In control cultures, 
the signals for pea3 and er81 were barely detectable above background levels. Since 
it was not possible to perform accurate densitometric measurements on the very faint 
hybridization signals from control cultures on these RNA dot blots, it was not 
possible to determine the quantitative extents to which the pea3 and er81 transcript 
levels were upregulated following FGF treatment. 
 Despite detection of a single erm mRNA transcript on a Northern blot of stage 
24/25 chick embryo head RNA, erm transcripts were not detected in RNA dot blots of 
stage 24/25 frontonasal and mandibular mesenchyme micromass cultures (data not 
shown). The number of erm mRNA transcripts may have been below the detection 
limit of the RNA dot blot assay. In addition, since densitometric quantification of 
pea3 and er81 mRNAs was not feasible in untreated control cultures of facial 
mesenchyme, more sensitive detection methods were required. Real-Time 
Quantitative PCR (RT-qPCR) is reported to be capable of detecting less than five 
copies of a target sequence (VanGuilder et al., 2008), and was therefore utilized for 
further expression analysis of pea3, erm, and er81 mRNA gene transcripts.  
4.2 Validation of RNA Isolation Methodology & RT-qPCR 
Optimization  
4.2.1 Isolation of high quality RNA   
 RT-qPCR consists of multiple rounds of enzymatic reactions, and is thus more 
sensitive to impurities which can interfere with fluorescence detection such as 
proteins, phenol/chloroform and other chemical solvents, than single-step enzymatic 
reactions (Bustin, 2005). Additionally, RT-qPCR requires RNA preparations to be 
free of contaminating genomic DNA (gDNA) as even low levels of gDNA 
contamination are capable of dramatically shifting quantification cycle (Cq) values. 
This is of particular importance for genes with a low copy number  
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Figure 4 RNA dot blot analysis demonstrating the effects of FGF2 treatment on 
pea3 and er81 mRNA levels in chicken stage 24/25 frontonasal and mandibular 
mesenchyme micromass cultures. Cultures were incubated for 2, 5, 12, or 20 h in 
medium supplemented with 20 ng/ml FGF2 or unsupplemented medium alone 
(control). (A) In stage 24/25 frontonasal and mandibular mesenchyme micromass 
cultures, FGF2 increased accumulation of pea3 gene transcripts at all time points. (B) 
er81 mRNA transcripts also increased at all time points in both frontonasal and 
mandibular mesenchyme micromass cultures treated with FGF2. (C) mRNA 
transcript levels of the constitutively expressed gapdh were similar in control and 
FGF2 treatment samples at most time points.  
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(Fleige and Pfaffl, 2006).  Accordingly, it was important to validate the quality of the 
RNA isolation protocol and the integrity of the resulting product.   
 Representative samples of total RNA prepared from stage 24/25 and 28/29 chick 
frontonasal and mandibular micromass and explant cultures were selected at random 
for quality and purity analysis using a standard sensitivity RNA microfluidic chip on 
an ExperionTM Automated Electrophoresis Station (Biorad, Hercules, CA, USA). The 
ExperionTM system generates a RNA quality indicator (RQI) score of 1-10 as a 
quantitative assessment of RNA integrity. The RQI scores are determined on the ratio 
of the 28S to 18S rRNA concentration of a sample as well as the sharpness of the two 
rRNA peaks. A score of 10 represents highest RNA integrity, while samples with RQI 
values below 7 are not recommended for downstream applications.  
 A representative electrophoretogram (Figure 5A) and virtual gel (Figure 5B) 
generated on the Experion™ system of for a sample of total RNA isolated from FGF2 
treated stage 24/25 mandibular mesenchyme are shown in Figure 5. A random group 
of isolated RNA samples consistently yielded RQI scores ranging between 9 and 10, 
and 28S:18S ratios ranging between 1.48-2.20 (Figure 5C).  Therefore, the RNA is of 
sufficiently high quality to perform RT-qPCR analysis. 
4.2.2 RT-qPCR profiles  
 Following validation of the RNA isolation methods, the optimal annealing 
temperature (Ta) for each gene specific qPCR primer pair was determined by 
performing a 12-step temperature gradient PCR at temperatures ranging from 52°C-
64°C. Amplified products from temperature gradient reactions were analyzed on 15% 
polyacrylamide gels. This verified that a single amplicon of the predicted size was 
generated for each gene specific primer set (Figure 6A-E).  
 The currently recommended practice is that qPCR amplification efficiency for 
each specific target gene and reference gene must be determined separately through 
the use of standard curves to enable accurate computations of relative gene expression 
levels (Ruijter et al., 2009). This is accomplished by performing qPCR on serially 
diluted cDNA samples (Nolan et al., 2006; Pfaffl, 2001). As shown in Figure 7A-E, 
the standard curves that were generated for the pea3, erm, and er81 target genes, as 
well as for the gapdh and RNA pol II b reference genes, yielded reaction efficiencies 
ranging from 86% - 105.2%. In accordance with the MIQE guidelines, NTC  
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Figure 5 RNA integrity analysis. (A) An electrophoretogram and corresponding 
virtual gel (B) for a representative total RNA sample isolated from a FGF2 treated 
stage 24/25 mandibular mesenchyme micromass culture as generated by the Biorad 
ExperionTM Automated Electrophoresis Station. The electrophoretogram shown in 
panel A corresponds to the RNA sample in lane 4 of panel B. Relative positions of the 
lower alignment marker, 18S rRNA, and 28S rRNA, are indicated.  (B) In the virtual 
gel shown in panel B, the left column (L) of the virtual gel represents the relative 
positions of the RNA standards, which ranged from 50 - 6000 base length. The 
prominent 18S and 28S rRNA bands of the different facial RNA samples are seen in 
lanes 1 to 4. The 28S/18S ratios and corresponding RQI values for these same 
representative samples are shown in (C).  
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Figure 6 RT-qPCR primer annealing temperature optimization. Each gene 
specific primer pair was tested in a 12-step temperature gradient PCR using cDNA 
prepared from stage 24/25 chick embryo head RNA in order to determine optimal 
primer annealing temperature (Ta). Optimal annealing temperatures were: pea3/55°C, 
erm/61°C, er81/58°C, gapdh and RNA pol II b/60°C. Melt curve analysis was 
performed immediately upon completion of the RT-qPCR reaction. Amplified 
products were separated by electrophoresis on 15% polyacrylamide gels to ensure 
amplification of a single gene product. (A) Primers for pea3 specifically amplified a 
single transcript of approximately 183 bp. Single products of approximately 146 bp 
and 91 bp were amplified by specific primers for erm (B) and er81 (C), respectively. 
(D) Primers for gapdh amplified a single transcript of approximately 96 bp. (E) A 
single transcript of approximately 112 bp for RNA pol II b was amplified. L*= Gene 
Ruler, 100 bp DNA ladder; L=Gene Ruler 50 bp DNA ladder (Thermo Scientific).   
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Figure 7 Determination of RT-qPCR amplification efficiencies for pea3, erm, 
er81, gapdh and RNA pol II b. Standard curves for (A) pea3, (B) erm, (C) er81, (D) 
gapdh, and (E) RNA polymerase II b were created by 5 fold (pea3, erm, er81) or 10 
fold (gapdh, RNA pol II b) serial dilutions of cDNA generated from RNA of stage 
24/25 chick embryo heads. All efficiencies and correlation coefficients fall within the 
acceptable range as recommended by BioRad and closely adhere to MIQE guidelines.  
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reactions, used to verify the absence of primer-dimer formation and reagent 
contamination, had Cq values at least 5 cycles greater than the least expressed 
transcript in experimental reactions (Bustin et al., 2009).  
4.3 RT-qPCR RNA Analyses of Pea3, Erm and Er81 Expression in 
Frontonasal and Mandibular Mesenchyme Cultures 
4.3.1 RT-qPCR analysis of FGF effects on micromass cultures   
 Micromass cultures of stage 24/25 chick embryo frontonasal and mandibular 
mesenchyme cells were incubated in the presence or absence of 20 ng/ml FGF2 for 2 
h, and collected for isolation of total RNA. cDNA was synthesized by reverse 
transcription, and used for RT-qPCR to determine the effects of FGF2 treatment on 
pea3, erm and er81 mRNA levels. The resulting qPCR data were statistically 
analyzed using the Relative Expression Software Tool (REST™).  
 As shown in Figure 8A, stage 24/25 frontonasal mesenchyme micromass cultures 
treated with FGF2 exhibited significantly increased levels of pea3 gene transcripts 
relative to untreated control cultures by approximately 2.8-fold (p = 0.003). In 
addition, er81 gene transcripts were significantly elevated in response to FGF2 by 
approximately1.6-fold relative to untreated controls (p = 0.022). However, erm gene 
transcript levels in stage 24/25 chick frontonasal mesenchyme were not significantly 
different in control versus FGF2 treated micromass cultures.  
 Similar to the frontonasal cultures, micromass cultures of stage 24/25 mandibular 
mesenchyme micromass cultures treated with FGF2 exhibited elevated levels of pea3 
gene expression by approximately 2.5-fold (p = 0.001) relative to untreated 
mandibular cultures (Figure 8B). Unlike the frontonasal micromass cultures, erm 
mRNA transcripts were increased approximately 1.6 fold in stage 24/25 mandibular 
mesenchyme micromass cultures treated with FGF2 relative to untreated controls     
(p  = 0.014). In addition, whereas FGF2 treatment elevated er81 expression in stage 
24/25 frontonasal micromass cultures, FGF2 treatment had no significant effect on 
er81 transcript levels in treated mandibular micromass cultures (Figure 8B). 
4.3.2 RT-qPCR analysis of explant cultures   
 Establishment of micromass cultures requires the dissociation of the facial 
mesenchyme tissue, resulting in loss of the original cell-cell contacts. Since the nature 
of cell-cell interactions might influence the response of prechondrogenic mesenchyme 
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Figure 8 Effects of FGF2 on pea3, erm, and er81 mRNA transcript levels in stage 
24/25 chick frontonasal and mandibular mesenchyme micromass cultures. 
Relative gene expression ratios generated using the REST™ qPCR data analysis 
software are represented as “box and whisker” graph. The graph for each gene of 
interest (i.e. pea3, er81, erm) indicates the level of mRNA expression in FGF2 treated 
cultures as a ratio of level in untreated control cultures. Therefore, the position of “1” 
on the “y” axis represents the median control value, while the position of the dotted 
line within the “box” for each gene of interest represents the median value for FGF2-
treated cultures. The top and bottom of each “box” represent the 75th and 25th 
percentile limits, whereas bars at the upper and lower ends of the “whiskers” 
represent the highest and lowest individual sample values. Asterisks (*) indicate 
FGF2 treatment effects that were statistically significant at p < 0.05.           
(Note: All RT-qPCR data shown in Figures 8 through 11 are represented in the same 
manner. In all cases, the relative expression values for the pea3, er81 and erm gene 
transcripts were normalized against the expression levels of the gapdh and RNA pol II 
b reference genes, as described in Materials and Methods). (A) REST analysis 
revealed that pea3 transcript levels were upregulated by a factor of 2.8-fold in FGF2 
treated stage 24/25 frontonasal mesenchyme micromass cultures relative to untreated 
controls (p = 0.003). In the same cultures, er81 transcript levels were elevated 1.6-
fold in response to FGF2 exposure (p = 0.022). In contrast, FGF2 treatment had no 
significant effect on erm transcript levels. (B) pea3 expression was upregulated 2.5-
fold in stage 24/25 mandibular micromass cultures treated with FGF2 (p = 0.001), and 
erm was upregulated 1.6-fold (p = 0.014). er81 mRNA levels were not significantly 
different in control and by FGF2 treated cultures.  
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cells to growth factors, we also examined the effects of FGF2 on pea3, erm and er81 
expression in facial mesenchyme explants, which preserved native intercellular 
contacts. Isolated stage 24/25 frontonasal and mandibular mesenchyme tissue 
explants were cultured in the presence or absence of 20 ng/ml FGF2 for 6 h, and 
harvested for total RNA isolation and cDNA synthesis, then pea3, erm, and er81gene 
expression was examined by RT-qPCR as described previously.   
 As shown in Figure 9A, in stage 24/25 frontonasal explants, FGF2 treatment 
upregulated pea3 expression approximately 2.9-fold relative to untreated control 
explants (p = 0.036). However, FGF2 treatment had no significant effect on either 
er81 or erm mRNA levels in stage 24/25 frontonasal explants. 
  Interestingly, in mandibular mesenchyme explant cultures, FGF2 exposure had 
no significant effects on either pea3 or er81 expression (Figure 9B). There appeared 
to be a trend towards elevated erm mRNA expression in response to FGF2 treatment 
in mandibular explant cultures, although the difference fell short of statistical 
significance (p = 0.055). This contrasts with the situation for frontonasal explants, 
where FGF2 elevated pea3 expression by 2.9-fold. It also differs from the situation 
observed for micromass cultures of both frontonasal and mandibular mesenchyme 
cells.  
4.3.3 Expression of pea3, erm, and er81 expression in facial mesenchyme 
micromass cultures of stage 28/29 relative to stage 24/25   
 Bobick and Kulyk (2007) reported the effects of FGFs on chondrogenesis in both 
frontonasal and mandibular mesenchyme micromass cultures are mediated by the 
MEK-ERK mitogen activated protein kinase (MAPK) pathway at stage 24/25 of chick 
embryo development (Bobick and Kulyk, 2004). In contrast, by stage 28/29 of 
development, pharmacological inhibition of the MEK/ERK pathway was no longer 
able to block the inhibitory effects of FGF on chondrogenesis in frontonasal 
mesenchyme cultures. This suggested that maturation of the frontonasal process is 
accompanied by a stage-related shift from an ERK-dependent to ERK-independent 
pathway of FGF signal transduction (Bobick et al., 2007).  
 Since the Pea3 group of transcription factors are putative targets of ERK 
phosphorylation, we questioned whether this stage-dependent shift in FGF signalling 
pathways might be correlated with stage-associated changes in levels of endogenous  
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Figure 9 Effects of FGF2 on pea3, erm, and er81 mRNA transcript levels in stage 
24/25 chick frontonasal and mandibular mesenchyme explant cultures. Box and 
whisker graphs representing relative gene expression levels as determined using 
REST™ qPCR data analysis software. (A) pea3 expression is upregulated 
approximately 2.9-fold in frontonasal explant cultures treated for 6 hours with FGF2 
relative to untreated controls (p = 0.036). Expression levels of erm and er81 were not 
significantly affected by FGF2. (B) Stage 24/25 mandibular mesenchyme explant 
cultures exhibited no significant changes in expression of pea3, erm, or er81 in 
response to FGF2 treatment. 
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pea3, er81, or erm expression in the facial mesenchyme. To address this possibility, 
expression levels of the Pea3 group of transcription factors were compared in 
micromass cultures of stage 24/25 versus stage 28/29 frontonasal and mandibular 
mesenchyme cells undergoing spontaneous chondrogenic differentiation in vitro.  
RNA for qPCR analysis was harvested after 2 days of culture in frontonasal 
micromass cultures. RNA was isolated from mandibular cells after 3 days, due to their 
slower rate of chondrogenic differentiation in micromass culture.  
 Comparisons of stage 28/29 relative to stage 24/25 frontonasal mesenchyme 
micromass cultures revealed no significant differences in levels of endogenous pea3, 
erm, or er81 gene expression (Figure 10A). However, surprisingly, stage 28/29 
mandibular mesenchyme micromass cultures exhibited significantly lower levels of 
pea3 mRNA transcripts relative to stage 24/25 mandibular cultures (p = 0.023) 
(Figure 10B). There were no significant differences in either erm or er81 transcript 
levels in stage stage 28/29 relative to stage 24/25 mandibular mesenchyme micromass 
cultures.  
4.3.4 Comparisons of endogenous pea3, erm, and er81 expression between 
mesenchyme of stage 24/25 frontonasal and mandibular facial primodia  
 Bobick and Kulyk previously reported that micromass cultures of stage 24/25 
frontonasal and mandibular mesenchyme have opposite responses to exogenous FGF 
(Bobick et al., 2007).  Since the Pea3 transcription factors are thought to be critical 
downstream effectors of FGF signalling, we questioned whether the frontonasal and 
mandibular cell populations might exhibit qualitative or quantitative differences in 
endogenous pea3, erm and/or er81 gene transcript levels. However, REST™ analysis 
revealed no significant differences between levels of pea3, erm, or er81 mRNAs in 
stage 24/25 mandibular micromass cultures relative to stage 24/25 frontonasal 
micromass cultures (Figure 11).  
 We also investigated if stage 24/25 frontonasal and mandibular explants, which 
retain their native cell contacts, exhibited qualitative differences in endogenous levels 
of Pea3 transcription factor expression. REST™ analysis revealed no significant 
differences between levels of pea3, erm, and/or er81 in stage 24/25 mandibular 
explants relative to stage 24/25 frontonasal mesenchyme (data not shown).  
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Figure 10 Endogenous pea3, erm, and er81 mRNA expression in stage 28/29 
chick frontonasal and mandibular mesenchyme micromass cultures relative to 
stage 24/25. (A) Analysis of RT-qPCR data using REST™ software revealed no 
significant differences in pea3, erm, or er81 transcript levels between stage 24/25 and 
stage 28/29 frontonasal mesenchyme micromass cultures. (B) Stage 28/29 mandibular 
mesenchyme micromass cultures exhibited significantly lower levels of pea3 mRNA 
transcripts relative to stage 24/25 mandibular mesenchyme micromass cultures (p = 
0.023). No significant differences were observed in levels of erm or er81 mRNA 
transcripts between stage 28/29 and stage 24/25 mandibular mesenchyme micromass 
cultures.  
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Figure 11 Endogenous pea3, erm, and er81 mRNA expression in stage 24/25 
chick mandibular mesenchyme relative to stage 24/25 frontonasal mesenchyme 
micromass cultures.  A box and whisker graph representation of relative gene 
expression levels obtained using the REST™ software tool. No significant differences 
were observed in pea3, erm, or er81 gene transcripts between stage 24/25 mandibular 
and stage 24/25 frontonasal mesenchyme micromass cultures. 
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4.4 RNA Dot Blot Validation of RT-qPCR Results 
4.4.1 RNA dot blot validation of micromass RT-qPCR results   
 RNA dot blot analysis was used to independently validate the measurements 
of pea3, erm, and er81 transcript levels as determined by RT-qPCR experiments. 
Aliquots of the total RNA remaining from a single micromass culture RT-qPCR 
experiment and a single facial mesenchyme explant experiment were used to 
determine the effects of FGF2 on pea3, erm, and er81 expression. To ensure there 
were sufficient amounts of RNA for dot blot analysis, the RNA from all three 
biological replicates of each experiment was pooled, then equivalent amounts were 
spotted onto nylon membranes, and probed with [32-P]-labelled cDNA probes for 
pea3, erm, and er81 as described in Materials & Methods Section 3.3.3. The 
hybridization signal for each gene of interest was normalized against the signal for 
constitutively expressed gapdh transcript to correct for any differences in sample 
loading.  
 In one set of stage 24/25 frontonasal mesenchyme cultures (3 biological 
replicates per treatment group), RT-qPCR analysis had indicated that 2 h FGF2 
treatment significantly increased both pea3 and er81 mRNA transcripts by factors of 
approximately 3.8- and 2-fold, respectively (data not shown). Subsequent dot blot 
analysis performed on pooled RNA from the same cultures confirmed these trends, as 
pea3 signal intensity was elevated approximately 4.7-fold and the er81 signal was 
approximately 5.6-fold higher in FGF2 treated cultures relative to controls (Figure 
12). In regard to erm expression, RT-qPCR analysis had revealed no significant 
difference between control and FGF2 treated stage 24/25 frontonasal micromass 
cultures. This was consistent with the RNA dot blots that indicated FGF affected erm 
transcript levels to a much lesser degree in comparison to its effects on pea3 and er81 
expression. 
 In the same RT-qPCR experiment, FGF2 treated stage 24/25 mandibular 
mesenchyme micromass cultures had significantly higher levels of both pea3 and erm 
mRNA transcripts by factors of approximately 2-fold (data not shown). Subsequent 
RNA dot blot analysis confirmed these trends, as pea3 and erm signal intensities were 
elevated approximately 1.5- and 2.7-fold respectively in FGF2 treated cultures  
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Figure 12 RNA dot blot analysis of FGF2 effects on pea3, er81, and erm 
expression in stage 24/25 frontonasal and mandibular mesenchyme micromass 
cultures. Micromass cultures were treated for 6 h in the presence or absence of 20 
ng/ml FGF2. For each treatment group, total RNA from three replicate cultures in a 
single experiment was pooled and used for dot blot analysis. The cultures were from 
an individual experiment in which the RT-qPCR data for that specific experimental 
run most closely matched the general trends revealed by REST™ analysis of pooled 
RT-qPCR data from all independent experimental runs. The panels on the left are 
autoradiographs of RNA dot blots hybridized with 32P-labelled cDNA probes for 
pea3, er81, erm and gapdh. The histograms represent the relative expression levels of 
pea3, erm, and er81 mRNAs as determined by densitometric measurements. To 
compensate for any differences in sample loading, the hybridization signals for each 
gene were normalized against the signal for the constitutively expressed gapdh 
transcript. (n = 1 for each treatment group) 
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relative to controls (Figure 12). In regard to er81 expression, RT-qPCR analysis had 
revealed no significant difference between control and FGF2 treated stage 24/25 
mandibular micromass cultures. This was consistent with the RNA dot blots that 
indicated FGF2 had minimal affect on er81 expression in comparison to its effects on 
pea3 and er81 expression.   
4.4.2 RNA dot blot validation of explant RT-qPCR results  
 In one set of three replicate stage 24/25 frontonasal explant RNA samples (3 
biological replicates per treatment group), the earlier RT-qPCR analysis had indicated 
that a 6 h FGF2 treatment significantly upregulated pea3 transcripts by 7.5-fold, erm 
mRNA transcripts by 3.4-fold, and er81 mRNA by 1.8-fold relative to parallel control 
cultures (data not shown). 
 Dot blot analysis performed on pooled RNA samples from the same set of 
cultures indicated that pea3 expression was upregulated 11-fold following FGF2 
treatment, while erm mRNA transcripts were elevated 7.8-fold relative to controls 
(Figure 13). Additionally, er81 mRNA transcripts in FGF2 treated frontonasal explant 
cultures were elevated 3-fold relative to controls as detected by RNA dot blot 
analysis. Thus, the RNA dot blot results confirmed the trends of FGF treatment on 
stage 24/25 frontonasal explant cultures that were previously determined by RT-
qPCR analysis.  
 In stage 24/25 mandibular explant cultures from the same experiment, RT-
qPCR analysis demonstrated a 5.8-fold increase in pea3 mRNA transcripts in 
response to 6 h FGF2 treatment relative to untreated controls (p = 0.053) (data not 
shown). RT-qPCR found erm transcript levels were also upregulated in response to 
FGF2 treatment by 2.6-fold (p = 0.045), while the er81 mRNA level was not 
significantly different than untreated controls (data not shown). Densitometric 
measurements performed on dot blots of pooled RNA samples from the same set of 
cultures indicated that pea3 expression was approximately 9-fold higher in FGF 
treated cultures and erm transcripts were upregulated approximately 3-fold relative to 
controls (Figure 13). In regard to er81 expression, RT-qPCR analysis revealed no 
significant difference between control and FGF2 treated stage 24/25 mandibular 
explant cultures. This is consistent with results obtained from RNA dot blots analysis 
demonstrating FGF treatment had the least affect on er81 expression (~ 1.9 fold) in 
comparison to its affects on pea3 and erm expression. As such, the RNA dot blot data  
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Figure 13 RNA dot blot analysis of FGF2 effects on pea3, er81, and erm 
expression in stage 24/25 frontonasal and mandibular explant cultures. The facial 
mesenchyme explants were treated for 6 h in the presence or absence of 20 ng/ml 
FGF2. For each treatment group, total RNA from three replicate cultures in a single 
explant experiment was pooled and used for dot blot analysis. The cultures were from 
an individual experiment in which the RT-qPCR data for that specific experimental 
run most closely matched the general trends revealed by REST™ analysis of pooled 
RT-qPCR data from all independent experimental runs. The panels on the left are 
autoradiographs of RNA dot blots hybridized with 32P-labelled pea3, er81, erm and 
gapdh cDNA probes. The corresponding histograms were obtained by densitometric 
quantification of the dot blot signals for the pea3, erm, er81 mRNAs.  These values 
were normalized against the signal for the constitutively expressed gapdh transcript to 
compensate for any differences in sample loading.  
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demonstrating the effects of FGF treatment on stage 24/25 mandibular explant 
cultures is consistent with the prior RT-qPCR analysis.  
4.5 Assessment of Chondrogenic Differentiation in Micromass 
Cultures of Frontonasal and Mandibular Mesenchyme  
4.5.1 Alcian blue histochemical detection of sulphated proteoglycans   
 The magnitude of the differences in pea3, erm, and er81 mRNA expression 
profiles in frontonasal versus mandibular mesenchyme cells were more modest than 
anticipated, in light of previous studies which reported that frontonasal and 
mandibular micromass cultures exhibit qualitatively opposite responses to exogenous 
FGFs or ERK pathway activation (Bobick and Kulyk, 2006; Bobick et al., 2007). 
Therefore, experiments were performed to determine whether these previous findings 
could be confirmed under the specific experimental conditions used in the present 
study. Micromass cultures of stage 24/25 and stage 28/29 frontonasal and mandibular 
mesenchyme cells were cultured in the absence or presence of 40 ng/ml FGF2, and 
collected after 2 or 3 days of incubation for histochemical staining with Alcian blue 
dye to determine cartilage matrix proteoglycan production. These experiments were 
also repeated in the presence or absence of 20ng/ml FGF2 (data not shown). In 
addition, total DNA accumulation in the presence or absence of FGF2 was determined 
in parallel replicate cultures as described in Section 3.5.2 of Materials and Methods.  
 For frontonasal mesenchyme micromass cultures, there was a significant 
reduction in the levels of Alcian blue stainable cartilage matrix proteoglycan 
accumulation in both stage 24/25 (Figure 14A) and stage 28/29 (Figure 14B) in 
response to FGF2 treatment (p < 0.001). This trend was consistent with the findings 
of Bobick et al. (2007), although the inhibitory effects of FGF2 on the frontonasal 
mesenchyme at both stages appeared to be of lesser magnitude than previously 
reported.  Consistent with the previous study, stage 28/29 mandibular mesenchyme 
micromass cultures exhibited a much lower level of spontaneous chondrogenesis than 
stage 24/25 mandibular mesenchyme, as evidenced by only faintly detectable levels 
of Alcian blue staining (Figure 14B).  
 Bobick et al. (2007) reported that FGF2 treatment stimulates cartilage matrix 
accumulation in stage 24/25 mandibular micromass cultures (Bobick et al., 2007). In 
contrast, my own experiments showed no visible difference in Alcian blue staining in
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Figure 14 Effects of FGF2 on accumulation of Alcian-blue stainable cartilage 
matrix accumulation in micromass cultures prepared from stage 24/25 and 28/29 
frontonasal and mandibular mesenchyme. Cultures were stained with Alcian blue 
histochemical dye after 2 or 3 days of incubation in the presence or absence of 40 
ng/ml FGF2. (A, B) Photographs of Alcian blue-stained micromass cultures of stage 
24/25 frontonasal and mandibular mesenchyme cells (A), and stage 28/29 frontonasal 
and mandibular mesenchyme cells (B) cultured with or without exogenous FGF2. (C) 
Histograms indicating relative levels of sulphated cartilage matrix glycosaminoglycan 
accumulation in control and FGF treated micromass cultures as determined by 
spectrophotometric quantification of eluted Alcian blue dye. Error bars represent the 
mean +/- standard deviation of measurements from six replicate cultures. Asterisks 
(*) denote values that are significantly different from the corresponding control at p < 
0.01. The data demonstrate that FGF treatment caused a significant decrease in Alcian 
blue stainable cartilage matrix accumulation in both stage 24/25 and stage 28/29 
frontonasal mesenchyme micromass cultures. In contrast, FGF2 treatment had no 
significant effect on Alcian blue stainable matrix production in either stage 24/25 or 
stage 28/29 mandibular mesenchyme cultures.  
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FGF2 treated mandibular mesenchyme cultures relative to untreated control cultures 
(Figure 14A). Elution of the Alcian blue dye and spectrophotometric quantitation 
confirmed that there was no significant effect of FGF treatment on sulphated GAG 
accumulation in the mandibular mesenchyme cultures (Figure 14C). As such, the  
opposing effects of FGF2 on stage 24/25 frontonasal and mandibular mesenchyme 
micromass cultures that were previously reported were not observed within the 
current study.  
4.5.2 Effects of FGF2 on DNA accumulation in frontonasal and mandibular 
mesenchyme micromass cultures   
 The Hoechst 33258 DNA fluorescence assay was used to investigate whether    
20 ng/ml FGF2 treatment differentially affected frontonasal and mandibular cell 
survival and/or proliferation, as monitored by measuring total DNA accumulation 
over the 2-3 day culture period. As demonstrated in Figure 15, FGF2 treatment had no 
significant effect on the overall DNA content of stage 24/25 frontonasal or 
mandibular micromass cultures. Similarly, FGF2 treatment showed no significant 
effect on the DNA content of stage 28/29 frontonasal mesenchyme micromass  
cultures (Figure 15B). In contrast, FGF2 treatment caused a significant increase in the  
DNA content of stage 28/29 mandibular mesenchyme relative to controls (p < 0.01).  
4.5.3 Effects of FGF2 treatment on sulphated GAG accumulation in 
frontonasal and mandibular mesenchyme micromass cultures 
 
 To ensure the unexpected results from the previous experiments were not due to a 
limitation of the Alcian blue staining method, an alternate method for detection of 
sulphated GAG was used. Stage 24/25 and stage 28/29 frontonasal and mandibular 
mesenchyme micromass cultures were cultured in the presence or absence of 40 
ng/ml FGF2. Relative amounts of sulphated GAG production were determined by 
measuring the ability of sulphated GAGs to bind the cationic dye 1,9 DMMB 
(Farndale et al., 1982; Whitley et al., 1989). Isolation and subsequent dissociation of 
the GAG-dye complex permits spectrophotometric quantification of sulphated GAG 
accumulation (Barbosa et al., 2003). An advantage of the DMMB method is that, 
unlike Alcian blue staining, it allows for quantification of sulphated GAGs secreted 
into the culture medium as well as sulphated GAGs deposited in the micromass cell 
layer.   
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Figure 15 Effects of FGF2 treatment on levels of total cellular DNA in stage 
24/25 and 28/29 chick frontonasal and mandibular micromass cultures. 
Micromass cultures were treated with 40 ng/ml FGF2 and collected after 2 or 3 days 
for analysis of cellular DNA content using the Hoescht 33258 fluorescence assay. (A) 
FGF2 treated stage 24/25 frontonasal and mandibular micromass cultures showed no 
differences in total DNA content relative to untreated controls. (B) The total DNA 
content of stage 28/29 frontonasal mesenchyme micromass cultures was not affected 
by FGF2 treatment, however stage 28/29 mandibular micromass cultures showed 
elevated levels of total DNA relative to untreated controls (p < 0.01). Error bars 
represent the mean +/- standard deviation of measurements from six replicate 
cultures.   
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Results of the DMMB assay indicated significantly less sulphated GAG was 
accumulated in the cell layer of stage 24/25 frontonasal mesenchyme 
micromasscultures treated with FGF2 than in controls (p < 0.001) (Figure 16A). This 
decrease was consistent with the results of the Alcian blue histochemical staining 
assay (Figure 14). There were no significant differences in the amount of GAG 
accumulation within the medium fraction of FGF2 treated stage 24/25 frontonasal 
micromass cultures relative to untreated to controls. Importantly, FGF2 treatment had 
no significant effect on sulphated GAG accumulation in either the cell layer or the 
medium fraction of stage 24/25 mandibular mesenchyme micromass cultures (Figure 
16B). This was consistent with the Alcian blue histochemical data (Figure 14), but 
contrary to a previous report that demonstrated FGF treatment of mandibular 
mesenchyme micromass cultures increased sulphated GAG accumulation (Bobick et 
al., 2007).  
 In stage 28/29 frontonasal mesenchyme micromass cultures, there was 
significantly decreased GAG accumulation in both the cell layer and medium 
fractions of FGF treated cultures relative to controls (p < 0.001), as shown in Figure 
17A. In control cultures of stage 28/29 mandibular mesenchyme, nearly all the 
sulphated GAG was deposited into the culture medium rather than the cell layer. 
FGF2 treatment had no significant effect on sulphated GAG accumulation in either 
compartment (Figure 17B).  Sulphated GAGs were barely detectable in control and 
FGF2 treated cellular fractions of stage 28/29 mandibular mesenchyme micromass 
cultures. These results were consistent with those obtained by Alcian blue 
histochemical staining: while FGF2 treatment inhibited chondrogenesis in both stage 
24/25 and stage 28/29 frontonasal mesenchyme micromass cultures, FGF2 treatment 
had no stimulatory or inhibitory effect on stage 24/25 or stage 28/29 mandibular 
mesenchyme micromass cultures. This strongly suggests the lack of chondro-
stimulatory effect observed in mandibular mesenchyme micromass cultures in 
response to FGF is not related to the specific methodology (i.e. either Alcian blue or 
1,9-DMMB) used to assess the extent of chondrogenic differentiation, but is rather 
due to changes in the cellular behaviour of mandibular mesenchyme.  
4.5.4 Immunostaining for Type II Collagen   
 Immunohistochemical staining was used to determine how FGF2 affected the 
expression of type II collagen, the other principal cartilage matrix component, in  
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Figure 16 Effects of FGF2 treatment on sulphated GAG accumulation in the 
cellular layer and medium fractions of stage 24/25 chick frontonasal and 
mandibular mesenchyme micromass cultures. Micromass cultures were treated 
with 40 ng/ml FGF2 and collected after 2 or 3 days for analysis of sulphated GAG 
accumulation in both the cell layer and culture medium using the DMMB assay. GAG 
accumulation measurements were normalized against total cellular DNA content to 
correct for any differences in cell number between control and FGF treated cultures. 
(A) In stage 24/25 frontonasal mesenchyme, FGF2 treatment significantly decreased 
sulphated GAG deposition into cell layer-associated cartilage matrix (p < 0.001), but 
had no effect on accumulation of sulphated GAGs within the surrounding culture 
medium. (B) In stage 24/25 mandibular mesenchyme, FGF2 treatment did not affect 
sulphated GAG accumulation in either the cellular layer or medium fractions. Error 
bars represent the mean +/- standard deviation of measurements from six replicate 
cultures.   
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Figure 17 Effects of FGF2 treatment on sulphated GAG accumulation in the 
cellular layer and medium fractions of stage 28/29 chick frontonasal and 
mandibular mesenchyme micromass cultures. Micromass cultures were treated 
with 40 ng/ml FGF2 and collected after 2 or 3 days for analysis of sulphated GAG 
accumulation using the DMMB assay. GAG accumulation values are normalized 
against µg of total cellular DNA.  (A) In stage 28/29 frontonasal mesenchyme, FGF2 
treatment significantly decreased sulphated GAG deposition into the micromass cell 
layer, as well as GAG secretion into the surrounding culture medium (p < 0.001). (B) 
In stage 28/29 mandibular mesenchyme, FGF2 treatment had no effects on sulphated 
glycosaminoglycan accumulation in either the cell layer or medium fractions. Error 
bars represent the mean +/- standard deviation of measurements from six replicate 
cultures. 
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micromass cultures of stage 24/25 and stage 28/29 frontonasal and mandibular 
mesenchyme. Stage 24/25 (Figure 18A) and stage 28/29 (Figure 18B) frontonasal 
mesenchyme micromass cultures exhibited decreased type II collagen accumulation 
following treatment with 20 ng/ml FGF2 relative to untreated cultures. These results 
paralleled the effects of FGF2 on cartilage matrix proteoglycan production as 
determined by both the Alcian blue staining and the DMMB assay. FGF2 treatment 
had no observable effect on type II collagen synthesis in stage 24/25 mandibular 
micromass cultures relative to controls (Figure 18A). Interestingly, FGF2 treatment 
visibly increased type II collagen accumulation in stage 28/29 mandibular micromass 
cultures relative to controls (Figure 18B), although no similar stimulatory effect was 
observed on cartilage matrix GAG deposition. 
4.6 Pea3, Erm, and Er81 Protein Expression Analysis 
4.6.1 Western blotting of micromass cultures    
 Western blotting was used to examine if observed changes in levels of pea3, erm, 
and er81 mRNA transcripts in micromass cultures were accompanied by similar 
changes in levels of the corresponding proteins. Stage 24/25 frontonasal and 
mandibular mesenchyme micromass cultures were established and treated with 20 
ng/ml FGF2 for periods of 2 to 48 hours. Following removal of the culture media, cell 
lysates were prepared.  Cell lysates containing equal amounts of total cellular protein 
were separated on SDS-polyacrylamide gels, transferred to nitrocellulose membranes, 
and probed with antibodies against Pea3, Erm, and Er81. Parallel Western blots were 
probed for detection of constitutively expressed Gapdh, and used to normalize relative 
signal intensities for Pea3 and Er81 proteins.   
 The Pea3 and Er81 antibodies successfully detected proteins of the appropriate 
size on Western blots (Figure 19A and D). Since antibodies specifically directed 
against chicken Erm are not currently commercially available, a polyclonal antibody 
against rabbit Erm was tested for its suitability. This particular Erm antibody proved 
to be unable to specifically detect chicken Erm within facial mesenchyme cell lysates 
as indicated by the presence of a large number of protein bands of various sizes on 
Western blots (data not shown). As such, only Pea3 and Er81 protein expression were 
examined in subsequent experiments. 
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Figure 18 Effects of FGF2 treatment on accumulation of type II collagen in stage 
24/25 and stage 28/29 frontonasal and mandibular mesenchyme micromass 
cultures. Cultures were incubated in either the presence or absence of 20 ng/ml FGF2 
and the accumulation of type II collagen in the cell layer was visualized by 
immunocytochemical staining with a monoclonal antibody against chicken type II 
collagen. (A) In stage 24/25 frontonasal mesenchyme micromass cultures, FGF2 
decreased accumulation of type II collagen relative to untreated control cultures. 
Levels of type II collagen in stage 24/25 mandibular mesenchyme micromass cultures 
were not affected by FGF2 treatment. (B) FGF2 treatment of stage 28/29 frontonasal 
mesenchyme micromass cultures reduced levels of type II collagen relative to 
untreated controls, but increased type II collagen accumulation in stage 28/29 
mandibular mesenchyme micromass cultures. (The “Negative Controls” indicate the 
amount of background staining obtained when type II collagen primary antibody was 
omitted from the immunohistochemical procedure.)    
 
  77 
Figure 19 Western blot analysis of the effects of FGF2 treatment on Pea3 and 
Er81 protein levels in micromass cultures prepared from stage 24/25 chick 
frontonasal and mandibular mesenchyme. The micromass cultures were cultured 
for 2, 6, 12, 24, or 48 hours in the presence or absence of 20 ng/ml FGF2. Relative 
levels of Pea3 and Er81 protein were determined by Western blot analysis using 
specific antibodies. Equivalent amounts of total protein were loaded in each lane. 
Values shown on graphs were obtained by NIH image analysis of relative band 
intensities on the Western blots, and were normalized to levels of constitutively 
expressed Gapdh. (A) Western blot of protein samples from frontonasal micromass 
cultures, together with histograms depicting relative levels of (B) Pea3 and (C) Er81 
proteins. (D) Western blot of protein samples from mandibular micromass cultures, 
with corresponding histograms depicting relative levels of (E) Pea3 and (F) Er81 
proteins.  
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In stage 24/25 frontonasal mesenchyme micromass cultures, FGF2 treatment had no 
marked effect on Pea3 protein levels relative to parallel control cultures at any of the 
time points examined (± 20% of control values) (Figure 19A and B). Western blots 
for Er81 protein of stage 24/25 frontonasal mesenchyme micromass cultures treated 
with FGF2 for 2 hours showed a slight increase in Er81 protein levels (33%)  
relative to untreated controls (Figure 19A). At all other time points, Er81 protein 
expression values in FGF2 treated cultures were within ± 10% of control cultures 
(Figure 19C).  
 Similarly, in stage 24/25 mandibular micromass cultures, FGF2 treatment had 
minimal effect on Pea3 protein expression at all time points examined (±20% of 
control cultures) (Figure 19D and E). Er81 protein levels also appeared to be 
unaffected by FGF2 treatment in stage 24/25 mandibular mesenchyme micromass 
cultures (±20% of control values) (Figure 19D and E). 
4.6.2 Western blotting of explant cultures       Western blotting was also used to examine if observed changes in levels of 
Pea3, Erm, and Er81 mRNA transcripts in explant cultures were accompanied by 
similar changes in levels of the corresponding proteins. Stage 24/25 frontonasal and 
mandibular mesenchyme tissue explant cultures were established and treated with 20 
ng/ml FGF2 for 6 hours. Cell lysates containing equal amounts of total protein were 
separated on SDS-polyacrylamide gels, transferred to nitrocellulose, and probed with 
Pea3 and Er81 antibodies. Levels of constitutively expressed Gapdh were used to 
normalize signal intensities for Pea3, Erm, and Er81 proteins. Antibodies were 
successful at detection of appropriately sized Pea3 and Er81 proteins on Western blots 
of explant cell lysates  (Figure 20A). 
 Pea3 protein expression was not markedly different in 6 hour FGF treated stage 
24/25 frontonasal mesenchyme explant cultures relative to untreated controls (±20%) 
(Figure 20A and B). In contrast, Western blots of stage 24/25 mandibular 
mesenchyme explants treated with FGF for 6 hours showed elevated levels of Pea3 
protein expression (~2.5 fold) relative to untreated controls (Figure 20A and B). 
FGF2 had no notable affect on Er81 protein expression in either stage 24/25 
frontonasal or mandibular mesenchyme explants relative to untreated controls (±20%) 
(Figure 20A and C). 
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Figure 20 Western blot analysis demonstrating the effects of FGF2 treatment on 
Pea3 and Er81 protein level in stage 24/25 frontonasal and mandibular 
mesenchyme explant cultures. Stage 24/25 frontonasal and mandibular mesenchyme 
explant cultures were treated with 20 ng/ml FGF2 for a period of 6 hours. Relative 
levels of Pea3 and Er81 proteins were determined by Western blot analysis of using 
specific antibodies. Equivalent amounts of total protein were loaded in each lane. 
Values shown on graphs were obtained by NIH image analysis of relative band 
intensities on the Western blots, and were normalized to levels of constitutively 
expressed Gapdh. (A) Western blot of protein samples from frontonasal explant 
cultures, together with histograms depicting relative levels of (B) Pea3 and (C) Er81 
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proteins. (D) Western blot of protein samples from mandibular explant cultures, with 
corresponding histograms depicting relative levels of (E) Pea3 and (F) Er81 proteins.  
5 Discussion  
 
 It is well established that FGF signalling plays essential roles in development 
and patterning of the vertebrate embryo (Ornitz and Itoh, 2001). For example, FGFR 
mutations are responsible for a number of congenital craniofacial skeletal defects 
(Winter, 1996). However, despite extensive literature documenting the diverse roles 
of FGF signalling during craniofacial development, comparatively little is known 
about the specific downstream effectors through which FGFs influence gene 
expression.   
 A previous study in our laboratory had reported that FGF treatment inhibits 
chondrogenesis in micromass cultures of frontonasal mesenchyme cells, whereas it 
stimulates chondrogenesis in mandibular mesenchyme cultures (Bobick et al., 2007). 
Nevertheless, FGF treatment increased ERK activation in both the frontonasal and 
mandibular mesenchyme cultures, and ERK inhibition blocked the effects of FGFs on 
both cell populations. This suggested that the mechanism responsible for the 
differential effects of FGFs on frontonasal and mandibular mesenchyme cells lies 
downstream of ERK activation (Bobick et al., 2007).  
 Transcription factors of the Pea3 subfamily (pea3, erm, and er81) are potential 
targets of ERK phosphorylation (O'Hagan et al., 1996) and are crucial components of 
the downstream effector pathway through which FGFs influence gene expression 
(Raible and Brand, 2001). Accordingly, the objective of my thesis was to examine 
whether cultures of embryonic chick frontonasal and mandibular mesenchyme cells 
exhibited differential expression patterns of the pea3, erm, and er81 genes, and 
whether FGF treatment has distinct effects on pea3 expression profiles in the two 
facial mesenchyme cell populations.  
 Collectively, my findings demonstrate that pea3, erm, and er81 gene 
expression levels are differentially altered in frontonasal and mandibular mesenchyme 
cells in response to FGF signalling. In addition, my data show that pea3, erm, and 
er81 exhibit subtly different, although overlapping, expression patterns in the 
frontonasal and mandibular cell populations, as well as stage-dependent changes in 
the expression profile of pea3 in mandibular mesenchyme. A summary of the pea3, 
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erm, and er81 mRNA expression data is provided in Table 3. The evidence supporting 
these conclusions is discussed below. 
5.1 The mRNA Expression Profiles of pea3, erm, and er81 Are Similiar 
Between Stage 24/25 Frontonasal and Mandibular Mesenchyme in the 
Absence of Exogenous FGF 
 
 A previous study, using in situ hybridization, had demonstrated that pea3, 
erm, and er81 gene transcripts are expressed within the head processes of chick 
embryos from stage 5 to stage 10 of development (Lunn et al., 2007). However, it was 
not yet known whether they were expressed specifically within the developing facial 
primordia. The RT-qPCR and RNA dot blot data in the current study clearly 
demonstrates that pea3, erm, and er81 are spontaneously expressed at both stage 
24/25 and stage 28/29 of development within chick frontonasal and mandibular 
mesenchyme (Figures 4, 10, 11, 12 and 13). To our knowledge, this investigation 
marks the first attempt to quantitatively analyse Pea3 transcription factor gene 
expression levels within the developing facial primordia of chick embryos.  
 In the absence of exogenous FGF2, the expression profiles of pea3, erm, and 
er81 between stage 24/25 frontonasal and mandibular explant control cultures were 
not significantly different. Similarly, no significant differences were observed in the 
expression profiles of pea3, erm, and er81 between stage 24/25 frontonasal and 
mandibular mesenchyme cells in micromass cultures (Figure 11). Collectively, this 
data strongly suggests that the endogenous expression profiles of pea3, erm, and er81 
are similar between chick frontonasal and mandibular mesenchyme prior to addition 
of exogenous FGF2. Thus, it is unlikely that pre-existing differences in pea3, erm, 
and er81 expression are responsible for differential responses of frontonasal and 
mandibular mesenchyme to FGF stimuli. 
 Transcripts for the Pea3 genes were still present in untreated frontonasal and 
mandibular mesenchyme explants 6 hours after tissue isolation, and at 12 to 32 h of 
incubation in control micromass cultures. Endogenous Pea3 transcription factor 
expression was sustained for approximately 32 h after establishment of micromass 
cultures (Figure 4). Notably, the overlying epithelia (endoderm and ectoderm) had 
been removed from the frontonasal and mandibular mesenchyme prior to 
establishment of both explant and micromass cultures. This indicates that expression 
of pea3, erm, and er81 in facial mesenchyme may occur independently of the  
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Table 3 A data summary of relative differences pea3, erm, and er81 mRNA 
expression based on RT-qPCR analyses.  
  
The REST™ pea3, erm, and er81 mRNA expression data analysis from all RT-qPCR 
experiments is summarized above. A ‘nsd’ indicates no significant difference. 
Significant changes in levels of pea3, erm, and er81 gene transcripts are indicated by 
arrows, while a ‘?’ indicates a trend nearing significance. S24/25 = stage 24/25; 
S28/29 = stage 28/29; FN = frontonasal mesenchyme; MD = mandibular 
mesenchyme;  = significant upregulation;  = significant down regulation.  
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sustained influence of adjacent epithelia, which are a significant source of FGF 
production in vivo (Stanier and Pauws, 2012). This contrasts with a previous report by 
Firnberg et al. (2007) suggesting FGF signalling is both necessary and sufficient for 
Pea3 transcription factor expression in facial development of chick embryos (Firnberg 
and Neubuser, 2002). However, the facial mesenchyme explants and micromass 
cultures in my experiments were maintained in medium supplemented with fetal 
bovine serum, which contains a variety of growth stimulatory factors (Zheng et al., 
2006). It is possible therefore, that certain serum factors might substitute for epithelia-
derived FGFs in sustaining expression of Pea3 genes in isolated facial mesenchyme. 
5.1.1 Exogenous FGF differentially alters expression profiles of pea3, erm, and 
er81 in stage 24/25 frontonasal and mandibular mesenchyme 
 
 The data indicates that the mRNA levels of pea3, erm, and/or er81 are 
increased in response to FGF2 treatment in frontonasal and mandibular mesenchyme 
explants and micromass cultures of chick embryos (Figures 4, 8, 9, 12, and 13). This 
is consistent with previous accounts in both chick and zebrafish embryos that the 
mRNA levels of Pea3 transcription factors are frequently upregulated in response to 
FGF signalling (Lunn et al., 2007; Roehl and Nusslein-Volhard, 2001).  
 As discussed earlier, pea3, erm and er81 expression levels were found to be 
similar in stage 24/25 frontonasal and mandibular mesenchyme in the absence of 
exogenous FGF. However, RT-qPCR analysis revealed differences in the relative 
extents to which FGF2 treatment altered expression of Pea3 genes in frontonasal and 
mandibular mesenchyme. A 6 h treatment with FGF2 increased pea3 mRNA 
expression in stage 24/25 frontonasal explants, but had no significant effect on pea3 
expression in mandibular explants (Figure 9).   
 Differential responses to FGF2 were also seen between stage 24/25 
frontonasal and mandibular mesenchyme cells in micromass cultures. A 2 h treatment 
with FGF2 elevated levels of pea3 gene transcripts in both frontonasal and 
mandibular mesenchyme (Figure 8).  In frontonasal mesenchyme exogenous FGF2 
also elevated levels of er81 mRNA but had no effect on erm expression. In contrast, 
exogenous FGF2 significantly increased levels of erm mRNA but had no effect on 
er81 expression in stage 24/25 mandibular mesenchyme.  
 Collectively, these findings indicate that the expression profiles of pea3, erm, 
and er81 in frontonasal and mandibular mesenchyme become distinct only after 
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exposure to exogenous FGF. This raises the possibility that the differences in Pea3 
transcription factor expression patterns that arise in response to FGF stimuli might 
subsequently lead to distinct chondrogenic outcomes in the two facial mesenchyme 
populations.  
5.1.2 Mandibular mesenchyme, but not frontonasal mesenchyme, exhibits a 
stage-dependent change in the expression profile of pea3  
 
 Bobick and Kulyk (2007) reported that the development of the chick 
frontonasal process was accompanied by a stage-dependent shift in the intracellular 
pathway responsible for transducing FGF signals (Bobick et al., 2007). Specifically, 
the effects of FGF on chondrogenesis in stage 24/25 frontonasal mesenchyme 
micromass cultures were dependent on ERK1/2 activation, whereas ERK inhibition 
was unable to block the chondro-inhibitory effects of FGFs on stage 28/29 frontonasal 
mesenchyme (Bobick et al., 2007). Therefore, I examined whether developmental 
maturation of the facial mesenchyme was correlated with stage-associated changes in 
the patterns of pea3, erm, and er81 expression. 
 Comparisons between micromass cultures of stage 24/25 and stage 28/29 
frontonasal mesenchyme revealed no statistically significant differences in the 
intrinsic profiles of pea3, erm, or er81 expression. Therefore, developmental 
maturation of the frontonasal primordium does not appear to involve a stage-
dependent change in its expression profile of Pea3 transcription factors. It would be 
important to examine whether FGF exposure differentially alters pea3, erm, and/or 
er81 expression between stage 28/29 and stage 24/25 frontonasal mesenchyme. 
However due to time constraints, FGF2 treatment experiments were only performed 
on cultures of stage 24/25 chick mesenchyme. 
 Interestingly, pea3 mRNA was expressed at significantly lower levels in stage 
28/29 mandibular micromass cultures compared to stage 24/25 mandibular cultures 
(Figure 10). As previously reported (Hoffman and Kulyk, 1999), my data confirmed 
that stage 28/29 mandibular mesenchyme displays a much lower capacity for 
spontaneous chondrogenesis in vitro than mandibular mesenchyme from stage 24/25 
chick embryos (Figures 14, 16, 17 and 18). Additional experiments would be required 
to determine whether reduced pea3 expression in stage 28/29 mandibular 
mesenchyme may contribute to the relatively lower capacity of these cells for 
spontaneous chondrogenesis in micromass culture.  
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5.1.3 Pea3 and Er81 proteins are expressed in micromass cultures of both 
frontonasal and mandibular mesenchyme  
 
 Western blot analysis demonstrated that both the Pea3 and Er81 proteins are 
endogenously expressed within the frontonasal and mandibular facial primordia of 
stage 24/25 chick embryos (Figures 19 and 20). Although antibodies specific for 
chicken Pea3 are not commercially available, I showed that antibodies against the 
mouse specific Pea3 protein could also be used for avian Pea3 detection. An 
examination of the pattern of Erm protein expression in chick facial mesenchyme was 
not possible, as a suitable antibody was not found.  
   Although pea3, erm, and/or er81 mRNA levels were differentially altered in 
response to FGF2 treatment in explant and micromass cultures of frontonasal and 
mandibular mesenchyme, the levels of Pea3 and Er81 protein were similar in control 
and  FGF2-treated cultures. A statistical analysis of the Western blot data for Pea3 
and Er81 protein expression was not possible as experiments were performed only 
once due to time constraints. As such, any interpretation of the Pea3 and Er81 protein 
expression is currently very tentative. It remains possible that exogenous FGF2 might 
have modest effects on Pea3 and Er81 protein levels in stage 24/25 frontonasal and 
mandibular mesenchyme. Additional experiments are necessary to determine if the 
changes in pea3 and er81 mRNA expression profiles correspond to similar subtle 
changes in their respective proteins. Furthermore, the overall protein abundance in a 
tissue does not necessarily parallel its corresponding gene transcript levels, due to 
post-transcriptional controls at the levels of RNA processing and RNA stability.    Previous studies have demonstrated that Pea3 transcription factor proteins are 
affected by phosphorylation and other post-translational modifications.  Thus, while 
no visible differences were observed in total Pea3 or Er81 protein levels in stage 
24/25 frontonasal and mandibular mesenchyme in response to exogenous FGF2, there 
may be effects on phosphorylation or other post-translational modifications that affect 
their transcriptional activities. Additional analyses to address these possibilities would 
be worthwhile.   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5.1.4 FGF inhibits chondrogenesis in micromass cultures of stage 24/25 
frontonasal mesenchyme, but has no effect on mandibular mesenchyme 
cultures 
 
 In an earlier study, Bobick et al. reported that FGF2, -4, and -8 exhibited 
opposite effects on chondrogenesis of chick frontonasal and mandibular mesenchyme 
cells in micromass cultures (Bobick et al., 2007). Specifically, whereas addition of 
FGF to frontonasal mesenchyme micromass cultures of both stage 24/25 and stage 
28/29 chick embryos inhibited chondrogenesis, FGFs stimulated chondrogenesis in 
mandibular mesenchyme micromass cultures of stage 24/25 and stage 28/29 chick 
embryos.  
 The data I obtained were only partially consistent with these results. As 
previously reported (Bobick et al., 2007), FGF2 treatment inhibited chondrogenesis in 
stage 24/25 and stage 28/29 frontonasal mesenchyme as evidenced by decreased 
Alcian blue stainable cartilage matrix deposition (Figure 14), reduced sulphated GAG 
accumulation in the cell layer and medium fractions (Figure 16 and 17), and 
decreased type II collagen production (Figure 18). In addition, I observed that stage 
28/29 mandibular mesenchyme exhibited a lower capacity for spontaneous 
chondrogenesis in micromass cultures compared to stage 24/25 mandibular 
mesenchyme cells (Figures 14, 16, 17, and 18), observations that are consistent with a 
previous report (Hoffman and Kulyk, 1999).  
 A notable difference in my data was observed in regard to the previously 
reported chondro-stimulatory effects of FGFs on mandibular mesenchyme micromass 
cultures (Bobick et al., 2007).  Under the specific conditions of my experiments, 
FGF2 exhibited no discernible effect (i.e. neither stimulatory nor inhibitory) on 
mandibular mesenchyme chondrogenesis as determined by Alcian blue stainable 
cartilage matrix deposition (Figure 14), sulphated GAG in the cell layer or culture 
medium (Figure 16 and 17), or type II collagen accumulation (Figure 18). Although 
opposite responses of frontonasal and mandibular mesenchyme were not observed, 
the cells within these two populations responded differently to exogenous FGF2. 
Specifically, while FGF inhibited chondrogenesis in stage 24/25 frontonasal 
mesenchyme, it had no effect on chondrogenic differentiation of stage 24/25 
mandibular mesenchyme.  
  88 
 Bobick and Kulyk demonstrated that a higher dose of FGF2 (40 ng/ml) 
reduced the average DNA content of stage 24/25 frontonasal and mandibular 
mesenchyme cultures to approximately 65 and 82% of the levels in untreated cultures 
(Bobick, 2006a). No similar reduction was observed at the same FGF2 dose in my 
experiments. Interestingly, while Bobick and Kulyk found no significant difference in 
the total DNA content of stage 28/29 mandibular micromass cultures in response to 
20 ng/ml FGF2, the same dose of FGF2 significantly increased the DNA content of 
these cultures in my experiments (Figure 15). This further indicates that under the 
experimental conditions employed in the current study, mandibular mesenchyme 
behaved differently in response to FGF signalling than was previously reported.  
 To investigate the potential causes of this discrepancy, several experimental 
parameters were examined. Bobick et al. (2007) observed the chondro-stimulatory 
effects of FGF on mandibular mesenchyme chondrogenesis using several different 
FGF concentrations (10, 20, and 40 ng/ml) and three different types of FGF (FGF2, -
4, and -8) (Bobick et al., 2007). My RT-qPCR and RNA dot blot experiments had 
consistently utilized FGF2, at a single dose of 20 ng/ml FGF2. As such, I performed 
additional experiments to examine if mandibular mesenchyme micromass cultures 
showed stimulatory responses when treated with FGF8 rather than FGF2 (data not 
shown). However, as with the FGF2 experiments, FGF8 treatment had no effect on 
chondrogenic differentiation of stage 24/25 and stage 28/29 mandibular mesenchyme 
micromass cultures. I further speculated that the discrepancy could relate to a lower 
sensitivity of stage 24/25 mandibular mesenchyme to respond to exogenous FGF2. If 
so, elevating the concentration of either FGF in the cell culture media would be 
expected to increase the magnitude of the response, perhaps revealing a chondro-
stimulatory effect. However, doubling the concentration of either FGF2 or FGF8 to a 
concentration of 40 ng/ml in the culture media still had no stimulatory effects on 
Alcian blue stainable cartilage matrix accumulation in stage 24/25 mandibular 
mesenchyme cells (data not shown).   
 Loss of activity during storage or lot-specific variability in the FGF2 stock 
might also have potentially affected its observed effects on facial mesenchyme 
micromass cultures. Therefore experiments were performed using aliquots of the 
same FGF2 stock used in the Bobick et al. (2007) study, as well as a fresh FGF2 stock 
purchased from a different supplier. In neither case did the FGF2 invoke a stimulatory 
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effect on mandibular chondrogenesis. Use of an alternate Alcian blue staining 
protocol also showed the same results as my previous experiments, as did experiments 
utilizing different stocks of FBS as the medium supplementation. Nevertheless, my 
results consistently demonstrated that FGF2 inhibited chondrogenesis in frontonasal 
mesenchyme micromass cultures but had no effect on chondrogenic differentiation of 
mandibular mesenchyme micromass cultures. This evidence strongly suggests that 
mandibular mesenchyme cells used in my experiments had an inherently different 
response to exogenous FGF2 than was previously reported. Since these results were 
observed throughout multiple independent assays, it is unlikely the discrepancy is 
related to systematic experimental error.  
 Interestingly, FGF2 treatment resulted in increased levels of type II collagen 
immunostaining in stage 28/29 mandibular mesenchyme micromass cultures (Figure 
18), which was consistent with the findings of Bobick et al. (Bobick et al., 2007). 
However, neither Alcian blue staining nor the DMMB assay showed any parallel 
stimulatory effect on matrix proteoglycan accumulation as was previously reported. 
The majority of the sulphated GAG produced by stage 28/29 mandibular mesenchyme 
micromass cultures was secreted into the surrounding culture media, rather than being 
retained in close proximity to the chondrocytes as primarily occurs with type II 
collagens. Thus, the disparity between patterns of pericellular sulphated GAG 
accumulation and type II collagen deposition in stage 28/29 mandibular mesenchyme 
micromass cultures may relate to differences in localization of the two chondrogenic 
markers.  
5.2 Advantages and Limitations of Methodology 
 Although not a specific objective of my thesis project, during the course of my 
experiments it became evident that critical precautionary measures are necessary to 
ensure the reliability and reproducibility of RT-qPCR data. Considerable time and 
effort was directed towards implementing a set of standard operating procedures in 
our laboratory for RT-qPCR experiments. These precautionary measures will be 
briefly discussed below.   
5.2.1 Experimental considerations for RT-qPCR  
 The very high sensitivity of RT-qPCR is particularly advantageous for gene 
expression analysis in developmental studies where the amount of embryonic tissue 
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available is extremely limited. This high sensitivity, however, also presents significant 
challenges within the laboratory environment. Contamination from non-template 
DNA within the laboratory (i.e. bacteria, human DNA, crossover contamination) can 
greatly influence RT-qPCR gene expression data. Numerous methods and procedures 
to minimize this risk are well-documented within the literature, however many 
laboratories fail to follow the rigorous precautions recommended by the MIQE 
guidelines (Bustin et al., 2009). Considerable time and effort was directed towards 
meeting the stringent requirements outlined by these guidelines.   
 In preliminary RT-qPCR trials, I relied solely on NCBI Primer Blast software 
to automatically design primers for amplification of pea3, erm, and er81. However, 
although these primers amplified a single amplicon of the appropriate size using 
conventional PCR, they proved to be unsuitable for RT-qPCR analysis as numerous 
gene transcripts were amplified in the presence of the SYBR green master mix. This 
was most likely the result of residual genomic DNA present after RNA isolation or 
contamination of PCR reagents with trace amounts of genomic DNA. As such, new 
pea3, erm, and er81 primers were designed to span putative intron/exon junctions, 
thus minimizing the risk of amplification of genomic DNA. In addition, while the 
cDNA synthesis and qPCR reaction mixtures were initially prepared on a standard 
laboratory bench, it subsequently proved to be important to prepare all RT-qPCR 
reaction mixtures in a biosafety cabinet that had been first decontaminated with 
bleach and UV irradiation.  
 Despite these initial precautionary measures, my early RT-qPCR reactions 
remained contaminated with non-template DNA as evidenced by multiple melt peaks 
and the presence of multiple amplicons when products were analyzed by acrylamide 
gel electrophoresis. Thus, it was deemed necessary to purchase new pipetters 
designated solely for RT-qPCR use in conjunction with barrier filter pipette tips. It 
was also necessary to include an on-column DNAse I digestion during the RNA 
isolation procedure and an additional DNase I digestion step during the reverse 
transcription reaction to maximally reduce levels of genomic DNA present prior to 
cDNA amplification by RT-qPCR. Validation of the RNA isolation procedure (Figure 
5) using a Biorad Experion microfluidic electrophoresis station further increased our 
confidence in our RT-qPCR data by ensuring RNA samples were of high integrity and 
purity.  
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 Uracil-DNA-glycosylase (UDG) catalyzes the N-glycosylic bond between 
uracil and the phosphodiester backbone of single- or double-stranded DNA, leaving a 
pyrimidinic site which blocks replication by DNA polymerase. Since the SYBR green 
master mix includes dUTP instead of dTTP, inclusion of UDG within the RT-qPCR 
reaction can effectively control crossover contamination (i.e. the products from 
previous reactions) (Longo et al., 1990). As such, our laboratory now includes UDG 
in all RT-qPCR reactions. The use of no-template controls (NTCs) in each RT-qPCR 
experiment is also essential to ensure the absence of primer-dimers and that reagents 
do not become contaminated over the course of experiments. Similarly, no reverse 
transcription reaction controls (NRTs) should also be performed to ensure sufficient 
removal of genomic DNA during the RNA isolation procedure. It is still possible, 
even when all the aforementioned precautionary measures have been taken, to 
occasionally observe amplification within NTC and NRT control reactions. In such 
instances, if amplification in the NTC or NRT controls occurred more than 5 cycles 
later than the least expressed transcript in experimental samples or beyond total 40 
amplification cycles, it was considered negligible as proposed by the authors of the 
MIQE guidelines (Bustin et al., 2009).  
 When a sufficient amount of experimental RNA sample is available, it is 
highly advantageous to utilize an alternative method of RNA expression analysis 
(e.g., northern blots, RNA dot blots, or RNAse protection assay) to validate the data 
obtained from RT-qPCR methodologies. Issues pertaining to non-template 
contamination of RT-qPCR reactions have much less of an impact upon these 
traditional RNA analysis techniques. In the present study, independent validation of 
some RT-qPCR data using the RNA dot blot method greatly increased our confidence 
in our RT-qPCR protocol. 
 All primers used in this study were optimized for annealing temperatures and 
were shown to specifically recognize a single target transcript (Figure 6).  The MIQE 
guidelines recommend amplification efficiencies should range between 90 to 110% 
(Bustin et al., 2009). Lack of sufficient precautionary measures to minimize the risk 
of non-template contamination typically results in amplification efficiencies above 
this range. The amplification efficiencies for most primer pairs used in my 
experiments were within the range of those recommended by the MIQE guidelines, 
with the exception of those for pea3 and er81. Although the amplification efficiencies 
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of our pea3 and er81 primer sets fell slightly below the stringent MIQE threshold 
(85.5% and 86% respectively), they were within the efficiency range recommended 
by the manufacturer of the specific RT-qPCR instrument employed in this study.  
(BioRad online support: www3.biorad.com/gexp/html/support/amp_central). 
 There are substantial financial implications when choosing RT-qPCR over 
traditional methods of RNA expression analysis. The fluorescently labelled dyes or 
probes required for real-time monitoring of the qPCR reaction are typically much 
more expensive than conventional PCR reagents. The initial financial investment in 
probe based RT-qPCR methods (e.g., Taqman probes) is greater than that of 
fluorescently labelled dyes (i.e. SYBR green). However, the costs associated with the 
extensive optimization/validation procedures required for reliable RT-qPCR data 
using SYBR green dye may diminish this financial benefit. The additional costs 
associated with RT-qPCR analyses may also limit the feasibility of temporal RNA 
expression profile analyses.  
 It is also interesting to note that while the preliminary RNA dot blot was 
unable to detect the presence of erm within micromass cultures of stage 24/25 
frontonasal and mandibular mesenchyme (Figure 4), subsequent RNA dot blots 
successfully detected erm mRNA (Figures 12 and 13). Failure to detect erm 
transcripts within these early experiments most likely related to cDNA probe 
synthesis and/or primer/template design, as subsequent experiments utilized an 
alternate primer-template combination. It may have been possible to utilize traditional 
RNA dot blot methodologies to examine pea3, erm, and er81 expression profiles. 
Although RNA dot blots lack the sensitivity of RT-qPCR, they are simple, 
inexpensive and relatively quick. As such, with additional embryonic tissue, RNA dot 
blots may have been beneficial for preliminary experiments into temporal changes in 
the expression patterns of the Pea3 subfamily of transcription factors.  
5.2.2 Variability in RT-qPCR data 
  
 The data from several individual experiments was pooled for final REST™ 
analysis. While the gene expression trends observed in RT-qPCR experiments were 
generally comparable between individual experiments, variation between the data 
obtained from individual experiments did exist. Notably, this type of variation was 
much less evident in experiments involving the micromass culture model than in 
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explants. The establishment of micromass cultures involves tissue dissociation to 
create a homogeneous high-density cell suspension, which is then spotted in replicate 
aliquots onto cell cultures plates. Thus, the greater homogeneity of the micromass 
culture system may explain the reduced variability observed in the resulting REST™ 
data, in comparison to the data obtained from explant experiments. Since the latter 
procedure does not involve a tissue dissociation step, it is necessary to use facial 
primordia excised from different individual embryos when establishing replicate 
explant cultures. Although all embryos were staged according to the methods of 
Hamburger and Hamilton (Hamburger and Hamilton, 1951), differences in external 
dimensions are evident between facial processes excised from separate embryos. Due 
to the greater thickness of facial explants in comparison to micromass cultures it is 
possible that exposure of mesenchyme cells to exogenous FGF2 in explant cultures 
was less uniform than in micromass cultures. Mesenchyme cells located within the 
innermost region of the facial explants may have been partially insulated from the 
effects of exogenous FGF2, further increasing the variability in pea3, erm, and er81 
mRNA expression values obtained from replicate explant cultures.  
5.2.3 Differences between pea3, er81, and erm expression profiles between 
micromass and explant cultures of stage 24/25 frontonasal and 
mandibular mesenchyme in response to exogenous FGF2 
 
 The effects of FGF2 on the expression profiles of pea3, erm, and er81 in stage 
24/25 frontonasal and mandibular mesenchyme as determined by RT-qPCR differed 
between explant and micromass cultures (Figures 8 and 9).  Specifically, whereas 
FGF2 increased pea3 expression in stage 24/25 frontonasal explants alone, it elevated 
pea3 expression in both stage 24/25 frontonasal and stage 24/25 mandibular 
mesenchyme micromass cultures.  Furthermore, while FGF2 treatment affected 
neither erm or er81 expression in explant cultures of frontonasal or mandibular 
mesenchyme, FGF2 exposure increased er81 expression in frontonasal mesenchyme 
micromass cultures and elevated erm expression in mandibular mesenchyme 
micromass cultures.  
 There are several possible explanations for the differences observed in the 
effects of FGFs on pea3, erm, and er81 mRNA expression profiles between 
micromass and explant cultures. While micromass cultures were treated with FGF2 
for 2 h, explant cultures were treated for 6 h. As mentioned previously, unlike 
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micromass cultures, explant cultures retain their native cell-cell contacts, and explants 
from individual embryos display slight differences in size and thickness. The native 
cell-cell contacts may directly contribute to the differences in Pea3 transcription 
factor expression profiles between micromass and explant cultures. Our experimental 
design had also assumed a longer FGF2 incubation period would be necessary to 
obtain comparable effects to those observed with 2 h FGF2 treatment of frontonasal 
and mandibular mesenchyme micromass cultures. The increased exposure of explant 
cultures to exogenous FGF2 may have contributed to the difference in pea3, erm, and 
er81 expression profiles in comparison to those for micromass cultures.  
5.2.4 Considerations for the use of commercially purchased fertilized eggs for 
research purposes 
 
 My study has raised a number of possible concerns in relation to the use of 
eggs from commercially bred chickens as a source of embryos for research purposes. 
First is the difficulty to control all factors that might be sources of biological 
variability. The rate of chick development is readily influenced by environmental 
factors, such as temperature and maternal nutritional status. Changes to either of these 
factors can imprint upon early stages of embryonic development and potentially 
impact cellular behaviour or tissue responses. Secondly, there may be gradual genetic 
drift in the population due to selective breeding aimed at generating chickens with 
more rapid postnatal growth and a correspondingly shorter time to market. Within my 
own experiments, the rates of chondrogenic differentiation in micromass cultures of 
both stage 24/25 frontonasal and mandibular mesenchyme cells appeared to be 
accelerated in comparison to earlier studies performed in our lab (W. Kulyk, personal 
communication).  
 The local commercial hatchery from which our fertilized eggs are purchased 
had previously distributed eggs from several different chicken breeds, including 
White Leghorn, Red Sussex, and Cornish Cross. However, all the eggs used for my 
experiments were from Giant Cornish Cross chickens, a breed deliberately developed 
for an exceptionally rapid rate of development.  
 It is possible that any of these factors, or a combination thereof, may account 
for the lack of chondro-stimulatory response of mandibular mesenchyme to FGF2 
signalling observed within the current study in comparison to that previously reported 
by Bobick and Kulyk (Bobick et al., 2007). 
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5.3  Conclusions 
 In summary, my research findings support the following main conclusions:  
• Mesenchyme cells from both the frontonasal and mandibular facial primordia 
of stage 24/25 and stage 28/29 chick embryos express mRNA transcripts for 
all three genes of the Pea3 transcription factor family (pea3, erm, and er81).  
• Western blot analysis indicates that frontonasal and mandibular mesenchyme 
cells also express at least two of these transcription factors (Pea3 and Er81) at 
the protein level. 
• Prior to stimulation with exogenous FGF2, the expression profiles of pea3, 
erm, and er81 mRNA transcripts are not significantly different between 
frontonasal and mandibular mesenchyme cells of the stage 24/25 chick 
embryo. This is true for facial mesenchyme explants and micromass cell 
cultures  
• Exposure to FGF2 alters pea3, erm, and/or er81 gene transcript levels in a 
differential manner in explant and micromass cultures of frontonasal versus 
mandibular mesenchyme of the stage 24/25 chick embryo. Specifially, in 
frontonasal explant cultures, pea3 gene transcripts were upregulated in 
response to FGF2, while erm and er81 were unaffected. Mandibular explants 
exhibited no changes in any of the Pea3 transcription factors following 
treatment with FGF2. In micromass cultures, pea3 was elevated in both 
frontonasal and mandibular mesenchyme following FGF2 exposure. In 
addition, er81 was upregulated in frontonasal mesenchyme, while erm was 
upregulated in mandibular mesenchyme following FGF2 treatment.   
• There is a stage-associated change in pea3 mRNA expression during 
developmental maturation of the mandibular primordium. Specifically, stage 
28/29 mandibular mesenchyme exhibited significantly lower levels of pea3 
expression than stage 24/25 mandibular mesenchyme. However, no stage-
dependent changes in Pea3 transcription factor expression were observed in 
frontonasal mesenchyme micromass cultures.  
• Contrary to a previously published study, my data indicate that stage 24/25 
chick frontonasal and mandibular mesenchyme cells exhibit distinct, although 
not opposite, chondrogenic responses to exogenous FGF2. Specifically, 
whereas exogenous FGF2 inhibited chondrogenesis in frontonasal 
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mesenchyme, it had neither an inhibitory nor stimulatory effect on mandibualr 
mesenchyme. 
5.4 Future Directions  
 My thesis research represents a first step toward examining the role of Pea3 
transcription factors in embryonic facial development. The results of this study have 
demonstrated that exposure to exogenous FGF differentially alters pea3, erm, and/or 
er81 gene expression profiles in mesenchyme derived from the frontonasal and 
mandibular primordia of the chick embryo. It is not yet apparent, however, whether 
there is any functional relationship between the distinct chondrogenic responses of 
stage 24/25 frontonasal and mandibular mesenchyme cells to FGF signalling and the 
differential effects of FGF on pea3, erm, and er81 mRNA expression levels in vitro.  
 In 2007, Bobick et al. reported that stage 24/25 and stage 28/29 frontonasal 
and mandibular mesenchyme exhibit opposing chondrogenic responses to exogenous 
FGF2, -4, and -8 (Bobick et al., 2007). Specifically, whereas exogenous FGF 
inhibited chondrogenesis of frontonasal mesenchyme, it stimulated chondrogenesis in 
mandibular mesenchyme. The current examination, however, found that while 
exogenous FGF2 inhibited chondrogenesis in frontonasal mesenchyme, it had no 
chondrogenic effect on mandibular mesenchyme. While attempts were made to 
determine the cause of this discrepancy, thus far, no specific factor has been 
identified. Future experiments to examine the effects of FGF on facial tissues from 
another breed of chicken to determine if genetic differences are responsible for this 
disparity would be useful.  
 In the current examination, statistical analysis of the Western blot data was not 
possible due to an insufficient number of replicates. While I observed no obvious 
differences in the levels of total Pea3 or Er81 proteins, it is possible exogenous FGF2 
may exhibit more subtle effects on Pea3 transcription factor expression in frontonasal 
and mandibular mesenchyme. Additional Western blot experiments are necessary to 
more thoroughly examine the effects of FGFs on Pea3 and Er81 protein expression.  
 The specific Erm antibody we tested for species cross-reactivity was not able 
to detect Erm in chicken lysates. However, there are a number of other Erm 
antibodies commercially available which could be tested for cross-reactivity to enable 
analysis of Erm protein expression in chick embryos. In addition, previous studies 
have demonstrated that Pea3 transcription factor proteins are affected by 
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phosphorylation and other post-translational modifications.  Thus, there may be 
effects on phosphorylation or other post-translational modifications that affect their 
physiological activities. Additional analyses to address these possibilities would be 
worthwhile.   
 Znosko et al. (2010) demonstrated that simultaneous knockdown of Pea3, 
Erm, and Er81 in zebrafish embryos using antisense morpholinos resulted in 
phenotypes resembling embryos deficient in FGF signalling (Znosko et al., 2010). 
Future experiments should be performed using RNA silencing methods (e.g., siRNA 
of shRNA treatments) to determine whether knockdown of pea3, erm, and er81 genes 
affects the ability of embryonic chick frontonasal and mandibular mesenchyme to 
undergo chondrogenic differentiation or to respond to exogenous FGFs. Znosko et al. 
(2010) had found that it was necessary to simultaneously knockdown expression of all 
three Pea3 genes in order to effectively block FGF signalling in zebrafish embryos. 
As such, it will be important to not only test the effects of pea3, erm and er81 gene 
knockdown individually, but to also examine how the simultaneous combinatorial 
knockdown of two or more of these transcription factors influences skeletal tissue 
differentiation in chick embryo facial primordia.  
 Another worthwhile area to investigate is whether there exists micro-
heterogeneity in patterns of pea3, erm, and er81 between specific sub-regions of each 
facial primordium, such as the mandibular process. Mina et al. (2002) demonstrated 
that within the developing mandibular process of chick embryos at least two 
functionally distinct regions exist (Mina et al., 2002). Morphogenesis within the 
lateral mandibular regions is dependent upon FGF8 signalling, while morphogenesis 
within the medial portion of the mandibular process occurs independently of FGF8 
signalling. Moreover, these two regions of mandibular mesenchyme were found to 
differentially respond to FGF signalling (Mina et al., 2002). If the Pea3 transcription 
factors play functional roles in mediating FGF responses in the developing mandible 
development, it may be possible to demonstrate regional differences in pea3, erm, and 
er81 expression profiles between the lateral and medial portions of the mandibular 
primordium. A combination of in situ hybridization methods and RT-qPCR analyses 
could be used to address this possibility.  
 It will ultimately be important to perform in vivo experiments to investigate 
the role of Pea3 transcription factors in chondrogenesis of facial mesenchyme, as the 
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current study relied solely on in vitro experiments.  For example, localized infection 
with retroviral viruses that express pea3, erm, and/or er81 coding sequences could be 
used to examine the effects of overexpression of these genes in specific facial regions 
of the chick embryo developing in ovo. Alternatively, conditional knockouts of the 
Pea3 transcription factors in individual facial regions of mouse embryos could help 
elucidate the roles of pea, erm, and er81 in vivo.  
 Such studies would provide greater insight into the molecular mechanisms 
through which FGFs affect chondrogenic differentiation in vitro, and may help 
elucidate the mechanisms responsible for the cellular signalling cascades regulating 
facial development in vivo.   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